Author Archives: author

Metformin Use and Mortality among Prostate Cancer Patients

DOI: 10.31038/IMROJ.2021654

Abstract

Purpose: Limited research has been conducted on the long-term use of metformin in patients with and without diabetes. Metformin is considered one of the most effective and affordable drugs used in patients with diabetes. However, only a few studies have examined the effects of metformin on prostate cancer mortality. This study aimed to understand the impact of metformin use on prostate cancer mortality among men, adjusted for diabetes.

Methods: SEER-Medicare data between 2007 and 2013 were used to extract demographic information from patients and cancer characteristics, including age, race, marital status, comorbidities (i.e., diabetes), and metformin use. Descriptive statistical analysis and logistic regression were performed to investigate the association between mortality rates (12, 60, and 120 months) and metformin use in men with prostate cancer with and without diabetes.

Results: We identified 222,289 prostate cancer patients enrolled in Medicare Part D. Among them, 17% received metformin, and 35% were diagnosed with diabetes. Among metformin users, a significantly higher proportion of cancer patients had diabetes (34.75%). Prostate cancer patients who took metformin had 0.54(AOR: 95% CI: 0.48-0.61), 0.58 (AOR: 95% CI: 0.55-0.62), and 0.56 (AOR: 95% CI: 0.54-0.59) lower odds of dying at 12 months, 60 months, and 120 months since the first diagnosis of prostate cancer than those without using metformin.

Conclusion: Metformin is one of the most commonly used diabetes treating agents. However, few studies have examined its role in treating prostate cancer. Our study showed that patients with prostate cancer who received metformin had a higher mortality rate than those who did not. Further studies are needed to determine whether metformin can positively affect patients with prostate cancer.

Keywords

Diabetes mellitus, Elderly, Metformin, Mortality, Prostate cancer, SEER-Medicare

Introduction

According to the Centers for Disease Control and Prevention (CDC), prostate cancer in the United States is the second leading cause of death, surpassed by heart disease, and one of the top four common cancers [1]. Furthermore, it is also one of the leading causes of cancer death among men of all races and populations of Hispanic origin populations [2,3]. Research from the Prostate Cancer Foundation revealed information about the probability that African American men are about 1.6 times more likely than all other men to get prostate cancer and twice more likely to die from it [4]. Specifically, approximately more than 200,000 new cases of prostate cancer were reported among men in 2017, and more than 30,000 men died from this cancer [5]. The Mayo Clinic estimates that approximately 60% of older adults (50 years or older) are at an increased risk of developing prostate cancer [6].

Diabetes mellitus is one of the most common comorbidities in patients with prostate cancer patients [7-9]. Diabetes is associated with an increased incidence of prostate cancer and mortality due to prostate cancer-specific mortality and/or all-cause mortality [10]. However, the biological link between diabetes and prostate cancer is poorly understood [11].

According to the American Diabetes Association, metformin is an inexpensive generic drug used to treat diabetes [12]. Recently, physicians have widely prescribed metformin because of its specific effects in treating and curing diabetes [13,14] as well as to prevent the development of diabetes [15].

Recent studies have shown that metformin can be used to reduce cancer incidence and mortality [16-19]. However, little is known regarding metformin in patients with prostate cancer. The results of studies evaluating the role of metformin in prostate cancer are contradictory. There are different perspectives on whether metformin use improves or deteriorates health conditions. One study showed that patients with diabetes mellitus taking metformin had a lower risk of prostate cancer [20]. However, a study conducted in Toronto found that metformin use is associated with an increased risk of being diagnosed with prostate cancer [21]. Another study suggested that metformin did not have proven benefits in cancer cells [22]. In 2020, the U.S. Food and Drug Administration (FDA) conducted recalls for different types of metformin. In other words, the FDA has not approved the use of certain types of metformin for patients with diabetes, as it can cause lactic acidosis [23]. Given these conflicting findings and the generally limited research, this study aimed to examine the association between metformin use and prostate cancer mortality, adjusted for diabetes status in patients. This study aimed to obtain data from Medicare beneficiaries (Medicare) and Surveillance, Epidemiology, and End Results (SEER).

Methods

Study Design and Data Source

Our study is a secondary analysis of merged data from the SEER and Medicare datasets, Medicare beneficiaries (Medicare), and Surveillance, Epidemiology, and End Results (SEER). The National Cancer Institute sponsors the SEER program [24]. Additionally, the dataset provided information on different stages of cancer and was designed to track cancer incidence and mortality rates in the United States [25]. Staging information is based on classification schemata that vary according to cancer site and year of diagnosis [26]. The SEER dataset also covers diverse populations with detailed cancer-related diagnoses and social demographics and covers more than 26% of the U.S. population in different demographics [26,27].

fig 1

Figure 1: Flow chart for the inclusion and exclusion of studies among Medicare beneficiaries diagnosed with diabetes and incident prostate cancer

The Medicare dataset consists of claim data and billing information, including inpatient, outpatient, and home health information [28]. Medicare is the primary health insurer for over 90% of the U.S. population aged 65 years and older in the U.S. [29]. All Medicare data were de-identified to protect patient information so that no protected health information could be traced to individual patients.

Combining the two datasets represents over 20% of the U.S. population from 1991 to 2013 (What Is SEER?, n.d.) [27]. The merging of the two datasets, SEER and Medicare claims, allows for a longitudinal analysis of cancer patients’ healthcare utilization and health outcomes.

Sample Selection

Our study included 222,289 patients, and all male patients aged 66 years and older who had prostate cancer diagnoses between January 1, 2007, and December 31, 2013, were selected from SEER-Medicare. Patients were excluded if their cancer diagnosis date was missing, death occurred before cancer diagnosis, or there was no follow-up medical care. We also excluded patients identified as having cancer through a death certificate. Furthermore, patients were excluded if they did not enroll in Medicare Part A, B, or D during the study follow-up. Some people may want to enroll in Medicare later could be that they have to pay a premium for Part A. It is also possible that a person who contributes to a health savings account (HSA) may consider delaying Medicare Part A [30]. Exclusion criteria were used to ensure that the long-term prostate cancer survivors/medication use data were complete for all patients. There were no missing values for age, metformin use, or diabetes based on the inclusion criteria. However, 27,188 (12.23%) individuals were classified as unknown for marital status, and 1,314 (0.59%) did not disclose their race/ethnicity.

Measures

Long-term prostate cancer survivors were defined as those who survived for >12 months after being diagnosed with prostate cancer [31,32]. Mortality at 12, 60, and 120 months was the key dependent variable in this study. Our study design also included the analysis of patients who survived more than 60 and 120 months after being diagnosed with prostate cancer. The initial selection of independent variables was based on both current data and existing literature [14,22]. Metformin use was a key independent variable. Most independent variables were categorized as binary variables. For example, age at diagnosis was divided into two different age groups, 66-74 and 75 years or older. Race/ethnicity was classified into four types: white non-Hispanic, black, Hispanic, and others. The five contrasting marital statuses were single, married, separated/divorced, widowed, and unknown. The presence of diabetes was identified using at least one hospital visit or more than one physician visit, with a primary or secondary diagnosis code for diabetes. The physician used several ICD-codes to identify diabetes, such as ICD-9-CM codes: 250.x0 or 250.x2. Diagnosis codes were extracted from Medicare Provider Analysis and Review (MEDPAR), carrier claims (NCH), and outpatients (OUTPAT). Metformin use was extracted from Part D Event (PDE).

Statistical Analysis

Descriptive statistics analysis using the chi-square test was used to investigate the association between mortality at 12, 60, and 120 months and each independent variable. Specifically, we examined the risk factors for patient mortality (12, 60, and 120 months) after being first diagnosed with prostate cancer and metformin use among men with prostate cancer. Additionally, we evaluated the mortality rates among those who used metformin and were diagnosed with incident prostate cancer with and without diabetes. Bivariate analyses examined the differences between basic demographic variables, metformin use, prostate cancer, diabetes, and mortality. Logistic regression models were built to estimate the direction and size of the association between live length and metformin use. Logistic regression was used to analyze the relationship between diabetes and mortality among metformin users. Several covariates, including age, race/ethnicity, and marital status, were used to adjust these models to estimate adjusted odds ratios and 95% confidence intervals for mortality of prostate cancer patients with or without diabetes using metformin.

Results

Baseline Characteristics

Table 1 shows the characteristics of the sample and bivariate associations between metformin use status and each independent variable and diabetes. The study sample included 222,289 patients with prostate cancer. Most of the patients were in the age group 66-74 116,344 (52.34%), and non-metformin users 96,654 (83.08%). In our study, there were more white non-Hispanic 170,598 (76.7%), and among the total population, there were more married 147,081 (66.17%) compared to other races and marital status. A significantly higher proportion of metformin users (32,076 patients) were diagnosed with diabetes, while there was still a high proportion of patients; 60,219 non-metformin users also had diabetes. Significant associations were also observed between diabetes, race/ethnicity, and white non-Hispanic individuals who were more likely to use metformin.

Table 1: Characteristics of the patient in a cohort of older adults with prostate cancer: SEER-Medicare database, 2007-2013.

Characteristics

Overall sample

n (%)

Metformin users

n (%)

Non-metformin

users n (%)

P-value

Unweighted Observations

n=222,289 (100%)

n=37,500 (16.87%) n=184,789 (83.13%)
Age

 <0.476

66-74

116,344 (100%)

19,690 (16.92%)

96,654 (83.08%)

75 or older

105,945 (100%)

17,810 (16.81%)

88,135 (83.19%)

Diabetes

<0.001

Yes

92,295 (100%)

32,076 (34.75%)

60,219 (65.25%)

No

129,994 (100%)

5,424 (4.17%)

124,570 (95.83%)

Race/Ethnicity

<0.001

White non-Hispanic

170,598 (100%)

26,181 (15.35%)

144,417 (84.65%)

Black non-Hispanic

29,344 (100%)

6,047 (20.61%)

23,297 (79.39%)

Hispanic

6,098 (100%)

1,666 (27.32%)

4,432 (72.68%)

Other

16,249 (100%)

3,606 (22.19%)

12,643 (77.81%)

Marital Status

<0.237

Married

147,081 (100%)

24,851 (16.90%)

122,230 (83.10%)

Unmarried

15,675 (100%)

2,676 (17.07%)

12,999 (82.93%)

Divorced /Separated

32,345 (100%)

5,338 (16.50%)

27,007 (83.50%)

Unknown

27,188 (100%)

4,635 (17.05%)

22,553 (82.95%)

Table 2 presents descriptive statistics of the sample with the three different outcomes, mortality at 12 months, 60 months, and 120 months among patients with prostate cancer patients. Age, race/ethnicity, marital status, metformin use, and diabetes were statistically significant differences (p-value < 0.05) for the three outcomes: 12 months mortality, 60 months mortality, and 120 months mortality after being diagnosed with prostate cancer. A total of 219,551 (98.77%) patients survived more than 12 months, and 2,738 (1.23%) died. There were 204,579 (93.18%) patients who survived more than 60 months, and 14,972 (6.82%) did not survive more than 60 months. There were 184,433 (90.15%) patients who survived more than 120 months, and 20,146 (9.85%) did not survive more than 120 months after being first diagnosed with prostate cancer.

Table 2: Descriptive statistics for mortality at 12 months, 60 months, and 120 months

Variables

One-Year Mortality (12 months) P-value Five-Year Mortality (60 months) P-value Ten-Year Mortality (120 months)

P-value

 

Yes

n (%)

No

n (%)

  Yes

n (%)1

No

n (%)0

  Yes

n (%)

No

n (%)

 

Age

<0.001

<0.001

<0.001

66-74

1,524 (1.31%)

114,820 (98.69%) 8,008 (6.97%) 106,812 (93.03%) 10,073 (9.43%)

96,739 (90.57%)

75 or older

1,214 (1.15%)

104,731 (98.85%) 6,964 (6.65%) 97,767 (93.35%) 10,073 (10.30%)

87,694 (89.70%)

Race

0.034

<0.001

<0.001

White-non-Hispanic

2,089 (1.22%)

168,509 (98.78%) 11,294 (6.70%) 157,215 (93.30%) 15,271 (9.71%)

141,944 (90.29%)

Black-non-Hispanic

383 (1.31%)

28,961 (98.69%) 2,176 (7.51%) 26,785 (92.49%) 2,912 (10.87%)

23,873 (89.13%)

Hispanic

92 (1.51%)

6,006 (98.49%) 495 (8.24%) 5,511 (91.76%) 637 (11.56%)

4,874 (88.44%)

Other

174 (1.07%)

16,075 (98.93%) 1,007 (6.26%) 15,068 (93.74%) 1,326 (8.80%)

13,742 (91.20%)

Marital Status

<0.001

<0.001

0.002

Married

1,733 (1.18%)

145,348 (98.82%) 9,617 (6.62%) 135,731 (93.38%) 13,380 (9.86%)

122,351 (90.14%)

Unmarried

185 (1.18%)

15,490 (98.82%) 1,124 (7.26%) 14,366 (92.74%) 1,419 (9.88%)

12,947 (90.12%)

Separated/ Divorced

373 (1.15%)

31,972 (98.85%) 2,136 (6.68%) 29,836 (93.31%) 3,061 (10.26%)

26,775 (89.74%)

Unknown

447 (1.64%)

26,741 (98.36%) 2,095 (7.83%) 24,646 (92.17%) 2,286 (9.28%)

22,360 (90.72%)

Metformin

<0.001

<0.001

<0.001

No

2,408 (1.30%)

182,381 (98.70%) 12,919 (7.08%) 169,462 (92.92%) 17,352 (10.24%)

152,110 (89.76%)

Yes

330 (0.88%)

37,170 (99.12%) 2,053 (5.52%) 35,117 (94.48%) 2,794 (7.96%)

32,323 (92.04%)

Diabetes

<0.001

<0.001

<0.001

No

1,433 (1.10%)

128,561 (98.90%) 7,469 (5.81%) 121,092 (94.19%) 10,106 (8.35%)

110,986 (91.65%)

Yes

1,305 (1.41%)

90,990 (98.59%) 7,503 (8.25%) 83,487 (91.75%) 10,040 (12.03%)

73,447 (87.97%)

Most of the patients aged 66 to 74 survived for over one year with a p-value = 0.001). With five-year mortality, most patients survived more than five years after being diagnosed with prostate cancer (p = 0.001). The third result showed that most of the patients stayed alive for more than 120 months, with a p-value of 0.001.

Race/ethnicity was statistically significant among the three outcomes, 12 months mortality (p-value=0.034), 60 months mortality (p-value < 0.001), 120 months mortality (p < 0.001) after the first diagnosis of prostate cancer. Among the same race/ethnicity, most patients, whether white-no Hispanic, black-no Hispanic, Hispanic, or other non-Hispanic, have survived more than half of the population for 12 months after being first diagnosed with prostate cancer.

Metformin use and mortality outcomes were statistically significant (p < 0.001). For the second outcome, the age group between 66 and 74 years had more than half of the population, and 106,812 (93.03%) survived more than 60 months after the first diagnosis of prostate cancer. Among the same race/ethnicity, most patients survived more than 60 months after the first diagnosis of prostate cancer, with a p-value of 0.001. Marital status was statistically significant for all three outcome variables, with a p-value of less than 0.005. The diabetes variables were also statistically significant for the three outcomes, with a p-value less than 0.001. Based on the three different outcomes of logistic regression, most patients survived for > 12, 60, and 120 months.

Table 3 describes the AOR for mortality at 12, 60, and 120 months in patients with prostate cancer treated with metformin. For this subgroup, metformin use between 66 and 74 years was 0.54 (95% CI: 0.48-0.61), 0.58 (95% CI: 0.55-0.62), 0.56 (95% CI:0.53-0.59) times less likely to die after prostate cancer was diagnosed within 12 months, 60 months, 120 months than those who were older than 74 years, respectively. Patients with diabetes were 1.49 (95% CI: 1.38-1.62), 1.64 (95% CI: 1.59-1.70), 1.66 (95% CI:1.60-1.72), 1.74 (95% CI: 1.69-1.79) times more likely to die after being diagnosed with prostate cancer within 12 months and 60 months, and 120 months compared to those without diabetes. Patients taking metformin were 0.54 (95% CI 0.48-0.61), 0.57 (95% CI 0.55-0.62), 0.56 (95% CI: 0.54-0.59) times less likely to die after prostate cancer compared to those who did not take metformin, respectively. Furthermore, black non-Hispanics had an AOR of 1.06 (95% CI: 1.01-1.11), 1.06 (95% CI: 1.02-1.11) times more likely to die within five years and ten years after the first diagnosis of prostate cancer. Hispanics are 1.19 (95% CI: 1.09-1.31) and 1.16 (95% CI: 1.06-1.26) times more likely to die within five and ten years after being diagnosed with prostate cancer than other races/ethnicities. The other marital status groups are 1.10 (95% CI: 1.03-1.17) times less likely to die after being diagnosed with prostate cancer. Otherwise, other marital statuses were not statistically significant.

Table 3: Adjusted odds ratios for mortality at 12 months, 60 months, and 120 months among prostate cancer patients.

Variables

One-Year Mortality (12 months) Five-Year Mortality (60 months) Ten-Year Mortality (120 months)
  OR 95% CI OR 95% CI OR

95% CI

Age
66-74

0.85

0.79-0.92* 0.94 0.91-0.97* 1.10

1.07-1.13*

75 or older

(ref.)

(ref.)

(ref.)

Race/Ethnicity
White-non-Hispanic

(ref.)

(ref.)

(ref.)

Black-non-Hispanic

1.02

0.91-1.14 1.06 1.01-1.11* 1.06

1.02-1.11*

Hispanic

1.21

0.98-1.50 1.19 1.09-1.31* 1.16

1.06-1.26*

Other

0.87

0.74-1.02 0.91 0.85-0.97* 0.87

0.82-0.93*

Marital Status
Married

(ref.)

(ref.)

(ref.)

Unmarried

0.99

0.85-1.16 1.10 1.03-1.17* 1.00

0.94-1.06

Separated/ Divorced

0.99

0.89-1.11 1.01 0.96-1.06 1.03

0.98-1.07

Metformin
No

(ref.)

(ref.)

(ref.)

Yes

0.54

0.48-0.61* 0.58 0.55-0.62* 0.56

0.54-0.59*

Diabetes
No

(ref.)

(ref.)

(ref.)

Yes

1.49

1.38-1.62* 1.66 1.60-1.72* 1.74

1.69-1.79*

Discussion

The age at diagnosis is an important predictor of prostate cancer mortality. Race/ethnicity can include various major risk factors such as genetic factors, medical practices such as screening, and complete reporting. Furthermore, there is conflicting evidence regarding the relationship between metformin use and mortality in patients with prostate cancer patients (He et al., 2019)33. The present study provides additional evidence that metformin use reduces the likelihood of mortality in patients with prostate cancer, regardless of diabetes. This finding is consistent with the existing evidence in the literature reviews that we found [33-36].

Furthermore, the results of this study showed that unmarried men were more likely to die within 60 months than married men. The findings showed that family support plays an important role in cancer outcomes; however, more research is needed to study the difference between different years of mortality versus unmarried status. Among metformin users, patients with diabetes have higher odds of mortality than those without diabetes. This may be due to the fact that metformin is the first-line medicine for diabetes. These findings support the notion that metformin is beneficial. These results indicate that metformin users with diabetes and prostate cancer are less likely to die. This finding may have been biased because we considered diabetes the only comorbidity in our analysis. Other comorbidities and diabetes may play a complex role in cancer-related mortality.

This observational study had several limitations. First, our study population included Medicare beneficiaries aged over 65 years. However, our findings may not be generalizable to younger age groups. Second, diabetes and cancer are two common diseases that are complex and have several subtypes. This study did not consider the different types or severity of diabetes, and other comorbidities were not included in the analysis. Therefore, this study may have excluded important risk factors related to patient outcomes. Furthermore, this study did not consider several important factors such as possible individual exposure to different types of treatment with an optimal potential dose, schedule, and duration of metformin treatment, which can contribute to different clinical outcomes.

Despite the study’s limitations, our study used a large sample size to identify the association between mortality due to metformin use among prostate cancer patients with or without diabetes. In general, metformin decreased the mortality of some patients with prostate cancer at 12, 60, and 120 months.

Conclusion

This study provides evidence that metformin use can reduce the mortality risk among patients with prostate cancer, including those with diabetes. The results showed that age, metformin use, and comorbidities influence prostate cancer. Socioeconomic disparities and prolonged use of metformin may explain the differences in mortality. Even the fact that metformin is an inexpensive drug with few side effects and anticancer effects in many types of cancer. Low socioeconomic status may explain why some patients have difficulty accessing treatment. Previous results concluded that our research identified population segments that may benefit from targeted interventions.

More studies, such as clinical trials, are needed to provide evidence of the effectiveness of metformin in patients with prostate cancer. Furthermore, we found a correlation between metformin and mortality in prostate cancer by adding additional information on comorbidities and various disparities. With more variables included in future research, more value can be added to identify better treatment options for older adults.

References

  1. Cancer Statistics—National Cancer Institute (nciglobal, ncienterprise) (2015) https://www.cancer.gov/about-cancer/understanding/statistics
  2. CDCBreastCancer (2021) Prostate Cancer Statistics. Centers for Disease Control and Prevention https://www.cdc.gov/cancer/prostate/statistics/index.htm
  3. Xiao H, Tan F, Goovaerts P, Adunlin G, Ali AA, et al. (2016) Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida. American Journal of Men’s Health 10: 285-295. [crossref]
  4. Prostate cancer in Black men: Risk factors, symptoms, and more. (2021) https://www.medicalnewstoday.com/articles/prostate-cancer-in-black-men
  5. USCS Data Visualizations. (n.d.). Retrieved March 31 (2021) from https://gis.cdc.gov/grasp/USCS/DataViz.html
  6. Prostate cancer—Symptoms and causes. (n.d.) (2021) Mayo Clinic. from https://www.mayoclinic.org/diseases-conditions/prostate-cancer/symptoms-causes/syc-20353087
  7. Ng HS, Koczwara B, Roder D, Vitry A (2018) Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study. Prostate Cancer and Prostatic Diseases 21: 403-410. [crossref]
  8. Roy S, Vallepu S, Barrios C, Hunter K (2018) Comparison of Comorbid Conditions Between Cancer Survivors and Age-Matched Patients Without Cancer. Journal of Clinical Medicine Research 10: 911-919. [crossref]
  9. Tseng (2011) Diabetes and Risk of Prostate Cancer. Diabetes Care 34: 616-621. [crossref]
  10. Feng X, Song M, Preston MA, Ma W, Hu Y, et al. (2020) The association of diabetes with risk of prostate cancer defined by clinical and molecular features. British Journal of Cancer 123: 657-665. [crossref]
  11. DeNoon DJ (2021) Why Does Diabetes Raise Cancer Risk? WebMD. from https://www.webmd.com/diabetes/news/20100616/why-does-diabetes-increase-cancer-risk
  12. Suissa S, Azoulay L (2014) Metformin and Cancer: Mounting Evidence Against an Association. Diabetes Care 37: 1786-1788. [crossref]
  13. Saraei P, Asadi I, Kakar MA, Moradi-Kor N (2019) The beneficial effects of metformin on cancer prevention and therapy: A comprehensive review of recent advances. Cancer Management and Research 11: 3295-3313. [crossref]
  14. Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: Results from a population-based case–control study. Cancer Causes & Control 20: 1617. [crossref]
  15. What Diabetes Drugs Improve Insulin Sensitivity? (n.d.). (2021) WebMD. from https://www.webmd.com/diabetes/diabetes-drugs-insulin-sensitivity
  16. Clements A, Gao B, Yeap SHO, Wong MKY, Ali SS, et al. (2011) Metformin in prostate cancer: Two for the price of one. Annals of Oncology 22: 2556-2560. [crossref]
  17. Hankinson SJ, Fam M, Patel NN (2017) A review for clinicians: Prostate cancer and the antineoplastic properties of metformin. Urologic Oncolog 35: 21-29.
  18. Nobes JP, Langley SEM, Klopper T, Russell-Jones D, Laing RW (2012) A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU International 109: 1495-1502. [crossref]
  19. Whitburn J, Edwards CM, Sooriakumaran P (2017) Metformin and Prostate Cancer: A New Role for an Old Drug. Current Urology Reports 18: 46.
  20. Zaidi S, Gandhi J, Joshi G, Smith NL, Khan SA (2019) The anticancer potential of metformin on prostate cancer. Prostate Cancer and Prostatic Diseases 22: 351-361. [crossref]
  21. Lee MJ, Jayalath VH, Xu W, Lu L, Freedland SJ, et al. (2021) Association between metformin medication, genetic variation and prostate cancer risk. Prostate Cancer and Prostatic Diseases 24: 96-105. [crossref]
  22. Raval AD, Mattes MD, Madhavan S, Pan X, Wei W, et al. (2016) Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer. Journal of Diabetes Research e2656814. [crossref]
  23. Research C (2019) FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain
  24. Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, et al. (2016) Mesothelioma in the United States: A Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival. Clinical Epidemiology 8: 743-750.
  25. Daly MC, Paquette IM (2019) Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare Databases: Use in Clinical Research for Improving Colorectal Cancer Outcomes. Clinics in Colon and Rectal Surgery 32: 61-68. [crossref]
  26. Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, et al. (2018) Overview of the SEER—Medicare Health Outcomes Survey Linked Dataset. Health Care Financing Review 29: 5-21. [crossref]
  27. What Is SEER? – National Cancer Institute (nciglobal, ncienterprise). (n.d.). [CgvInfographic]. Retrieved March 31, 2021, from /research/areas/public-health/what-is-seer-infographic
  28. CMS announces new payment model to improve quality, coordination, and cost-effectiveness for both inpatient and outpatient care | CMS. (n.d.). Retrieved July 5, 2020, from https://www.cms.gov/newsroom/press-releases/cms-announces-new-payment-model-improve-quality-coordination-and-cost-effectiveness-both-inpatient
  29. Moon M (1996) What Medicare Has Meant To Older Americans. Health Care Financing Review 18: 49-59.
  30. Fact Sheet: Deciding whether to enroll in Medicare Part A and Part B when you Turn 65. (n.d.). FACT SHEET, 15.
  31. Brenner H, Arndt V (2016) Long-Term Survival Rates of Patients with Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis. Journal of Clinical Oncology https://doi.org/10.1200/JCO.2005.11.148
  32. Stokes ME, Black L, Benedict Á, Roehrborn CG, Albertsen P (2010) Long-term medical-care costs related to prostate cancer: Estimates from linked SEER-Medicare data. Prostate Cancer and Prostatic Diseases 13: 278-284. [crossref]
  33. He K, Hu H, Ye S, Wang H, Cui R, et al. (2019) The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis. Scientific Reports 9: 2218.
  34. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, et al. (2012) Cancer mortality reduction and metformin: A retrospective cohort study in type 2 diabetic patients. Diabetes, Obesity and Metabolism. 14: 23-29. [crossref]
  35. Landman GWD, Kleefstra N, Hateren KJJ, Groenier KH, Gans ROB, et al. (2010) Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16. Diabetes Care 33: 322-326. [crossref]
  36. Zingales V, Distefano A, Raffaele M, Zanghi A, Barbagallo I, et al. (2017) Metformin: A Bridge between Diabetes and Prostate Cancer. Frontiers in Oncology 7: 243.

Can Full-Fat Dairy Intake Contribute to Preventing Diabetes and Cardiometabolic Issues?

DOI: 10.31038/EDMJ.2022611

Abstract

This perspective article aimed to develop and at least partly address an important question if full-fat dairy intake can improve public health via contributing to diabetes and cardiometabolic issues prevention. Type 2 diabetes and associated complexities are related to lifestyle and nutritional-exercise regimens. Traditionally, the intake of low-fat or even fat-free dairy products has been suggested to reduce risks from metabolic complexities. This may be partly due to saturated fatty acids in full-fat dairy products that might theoretically cause cardiometabolic issues. However, the growing evidence suggests that full-fat vs. low-fat dairy have neutral or even beneficial effects on cardiometabolic health and diabetes prevention. Dairy products such as milk and yoghurt are considered functional foods that consist of various elements including vitamins, minerals, probiotics, anti-inflammatory, and bioactive molecules that work for body health in organized fashions. Hence, to sum up, full-fat dairy intake for diabetes and cardiometabolic issues prevention needs further profound assessment to enable optimizing the current public opinions.

Keywords

Full-fat dairy, Diabetes, Public health, Tradition, Science

Introduction and Discussion

This perspective article aimed to develop a question and discuss if full-fat dairy intake can contribute to preventing diabetes and cardiometabolic issues. Fresh milk and its products mainly yoghurt and cheese are considered health-promoting natural foods. However, from public perspective, full-fat dairy intake may be related to higher blood bad cholesterol and greater risks from diabetes and cardiometabolic issues [1,2]. As such, reduced-fat or even free-fat dairy intake has been recommended [3]. This position, however, has been challenged recently in various studies, suggesting neutral or even positive effects of full-fat dairy intake on glucose metabolism and cardiometabolic health [4,5].

The correlation of dairy fat intake and cardiovascular diseases incidence has been weak [3]. It seems that individual saturated fatty acids (SFA) possess exclusive biochemical functions that might not be evaluated as a group. For example, myristic acid (14:0) is an activator of conversion of α-linolenic acid to docosahexaenoic. It is also needed for the activation of proteins during biochemical pathways. Myristic acid and lauric acid (12:0) exhibit capacities to decrease blood bad cholesterol (LDL) [6]. Also, SFA particularly with shorter chains possess some potential to increase blood good cholesterol (HDL) and improve LDL/HDL ratio in yogurt eaters [4,7]. Thus, it has become possible to challenge the notion that SFA lead to increased blood cholesterol and cardiometabolic diseases. Realistically, a number of other effectors including social bond, nutrition, exercise, lifestyle, smoking, and stress are involved in the etiology of cardiometabolic diseases and cancer. Inflammation appears to an influential factor causing cardiovascular issues [7]. Dairy lipids such as phospholipids and sphingolipids may exhibit anti-inflammatory effects that can help prevent cardiovascular issues [7]. Furthermore, angiotensin-converting enzyme (ACE) inhibitors of milk protein may contribute to lowering blood pressure and its related heart coronary issues [8].

Notable, whole dairy products should be looked at as exclusive complexes because they possess unique functional roles [5]. Thinking of food matrices rather than single elements provides a more precise assessment of full-fat dairy products for diabetes and cardiometabolic diseases prevention [9]. Dairy nutrients, all in all, as a multipurpose complex can improve nutrient assimilation and function [7]. As such, decreasing the fat content of milk or yogurt may alter physiochemical structure and nature of dairy lipids. This may have unfavorable health outcomes.

In a large study with people from diverse countries and different continents, lower risk of mortality and cardiovascular issues were found in whole dairy consumers [10]. Moreover, full-fat dairy intake may have neutral or even beneficial impacts on cardiovascular health, with decreased risk of diabetes in yogurt eaters [11]. The odd-chain SFA are viewed as biomarkers of dairy fat intake and cardiometabolic diseases risks. Pentadecanoic acid (15:0), heptadecanoic acid (17:0) and trans-palmitoleic acid (t16:1n-7) are some examples [12]. Measuring these biomarkers in older adults suggested an inverse relationship between dairy fat biomarkers with cardiovascular diseases and mortality [12]. Overall, it has become a challenging question if full-fat dairy intake can help prevent cardiometabolic diseases and diabetes or even obesity. Addressing this question will possess important implications for improving public health in the new times.

Implications

Based on the recently enhanced understanding of the biological functions of dairy fats and other nutrients, seemingly, full-fat dairy intake may have no harmful effects on cardiovascular health. Instead, lifestyle, social bond, stress, and inflammation may be viewed as more important effectors. Favorable impacts of full-fat dairy intake on diabetes and related complexities may be seen in yogurt consumers. It is recommended that the worldwide public update/refine its understanding on full-fat dairy intake association with human wellbeing. This recommendation will have important implications for improving public health in the new era.

Acknowledgment

Nature is acknowledged for its inspirations towards innovative science perspectives.

References

  1. Nikkhah A., B. Bekik (2012) Science and pseudo-science of milk implications for human health. In: Milk production, Nova Science Publisher, New York, USA, 15-20.
  2. Turpeinen O (1979) Effects of cholesterol lowering diet on mortality from coronary disease and other causes. Circulation 59, 1-7. [crossref]
  3. Lordan R, Tsoupras A, Mitra B, and Zebetakis I (2018) Dietary fats and cardiovascular disease: Do we really need to be concerned? Foods 7, 1-34.
  4. Nikkhah A (2014) Yogurt the most natural and healthy probiotic: History Reveals. Journal of Probiotics and Health 1-2.
  5. Hirahatake KM, Astrup A, Hill OJ, Slavin LJ, Allison BD, Maki CK (2020) Potential cardiometabolic health benefits of full-fat dairy: The evidence base: Advanced in Nutrition 11, 533-547. [crossref]
  6. Nettleton JA, Legrand P, Mensink RP (2015) Issfal (2014) debate: It is time to update saturated fat recommendations. Annals of Nutrition and Metabolism. [crossref]
  7. Lordan R and Zebetakis I (2017) The anti-inflammatory properties if dairy lipids. Journal of Dairy Science 100, 4197-4214.
  8. Nikkhah A (2012) Milk for humans: Evolving perceptions of an all-time mother science. Russian Agricultural Sciences 38, 328-336.
  9. Torning TK, Bertram HC, Bonjour Jp, De Groot L Dupont D, Feeney E, et al. (2017) Whole dairy matrix or single nutrients in assessment of health effects: current evidence and knowledge gaps. The American Journal of Clinical Nutrition 105, 1033-1045. [crossref]
  10. Dehghan M, Mente A, Rangarajan S, Sheridan P, Mohan V, et al. (2018) Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 392, 10161. [crossref]
  11. Yu E and Hu FB (2018) Dairy products, dairy fatty acids and the prevention of cardiometabolic disease: A review of recent evidence. Current Atherosclerosis Reports 20, 24. [crossref]
  12. de Oloveira Otto MC, Lemaitre RN, Song X, King IB, Sicovick DS, Mozaffarian D (2018) Serial measure of circulating biomarkers of dairy fat and total and cause-specific mortality in older adults: the Cardiovascular Health Study. American Journal of Clinical Nutrition 108, 476-484. [crossref]

Learning US Assisted Neuraxial Technique during a Pandemic: Case Report

DOI: 10.31038/CST.2022714

Abstract

We present the case of an anaesthetic registrar learning ultrasound assisted neuraxial anaesthesia during the COVID-19 pandemic. An 81-year-old patient with significant scoliosis required anaesthesia for a revision hip replacement following periprosthetic fracture. Despite the communication difficulties presented by wearing full personal protective equipment to reduce potential transmission of COVID-19 an experienced consultant anaesthetist was able to demonstrate the relevant lumbar spine sonoanatomy to a year six anaesthetic registrar. The registrar was then able to perform a first pass neuraxial procedure in the left lateral position under general anaesthesia. The anaesthetic had good effect and the patient was comfortable post operatively with minimal opiate requirements. The patient was discharged to his home from hospital 14 days later.

Keywords

Ultrasound, Spinal anaesthesia, Neuraxial, Case report

Introduction

Spinal anaesthesia is a common technique for hip and knee replacements and revisions. It is not uncommon to encounter difficulty in finding the intervertebral space using a landmark technique in this population; who tend to be elderly with osteoarthritic changes to the spine, may have scoliosis and may have had previous spinal surgery. Difficult anatomy can lead to multiple passes of the spinal needle with the inherent increased risk and discomfort for the patient. There is evidence that pre-procedural ultrasound imaging can reduce the number of needle passes [1-4]. We report this case of ultrasound imaging guiding a senior anaesthetic trainee to perform a first pass spinal anaesthetic technique on an asleep patient with scoliosis and previous spinal surgery requiring surgery for periprosthetic femoral fracture during the 2020 Covid-19 pandemic.

Case Report

An 81-year-old male was listed for a right revision hip replacement following periprosthetic fracture during the 2020 Covid-19 pandemic. The patient had well controlled hypertension, long-standing right sided sciatica and scoliosis with an American Society of Anaesthesiologists physical status IIE. He had had previous bilateral hip replacements, lumbar decompression and recent cervical decompression. Preoperative investigations showed a haemoglobin of 107 g/L; his Covid-19 swab was negative. An MRI report described exaggerated lumbar lordosis and significant scoliosis with moderate to severe canal narrowing at L4/5.

The patient was consented for general anaesthesia with spinal anaesthesia for analgesia. Anaesthesia was commenced in the operating theatre with staff wearing full Personal Protective Equipment (PPE) including long sleeve gown, two pairs of gloves, a visor and an FFP3 mask or equivalent (local hospital policy at this time). Anaesthesia was induced with propofol, fentanyl and rocuronium and was maintained with sevofurane in a mixture of oxygen and nitrous oxide. The patient’s trachea was intubated orally using a McGrath video-laryngoscope with a size 8 mm (ID) standard tracheal tube. Following intubation, a radial arterial line was sited and the patient placed in the left lateral position. A consultant anaesthetist with extensive experience in the use of ultrasound assisted neuraxial techniques scanned the patient’s back with a curvilinear probe. Using ultrasound, the consultant demonstrated the sacrum and identified the lumbar intervertebral spaces showing narrow gaps and a longitudinally rotated spine. Spinous process shadow on the ultrasound showed that in the left lateral position the midline was significantly superior to the previous decompression scar (Figure 1).

fig 1

Figure 1: Picture of patient’s back showing expected midline (solid line) and actual spinous processes (dashed line) with rectangle indicating pre-procedure curvilinear probe position and arrow indicating entry point and direction of needle.

The optimal space was identified (L3/4), distance to the laminae was calculated to be 4 cm allowing the depth of the spinal canal to be estimated at 4-5 cm. Angulation of the probe suggested the needle should be aimed towards the right shoulder to penetrate the dura. The site was marked and the year six anaesthetic trainee donned sterile gown and gloves whilst the site was cleaned with 0.5% chlorhexidine spray. The trainee was experienced in neuraxial procedures using landmark technique but had no experience using ultrasound imaging of the spine. Despite muffled voices from wearing the FFP3 masks the consultant conveyed the information provided by ultrasound to the trainee. The trainee punctured the dura on the first pass using a needle angle he would not have used otherwise. Local anaesthetic in the form of 0.5% plain bupivacaine was injected and surgery was allowed to commence. During surgery the patient did not respond to surgical stimulus indicating functioning spinal anaesthetic. Surgery lasted 180 minutes and at the end we performed femoral and lateral cutaneous nerve blocks. The patient stayed in an overnight recovery area where his pain was described as mild and settled with 10 mg oral morphine. The patient was discharged home 14 days after surgery.

Discussion

Spinal anaesthesia is a common technique for lower limb surgery, but it can be challenging in patients with scoliosis or previous spinal surgery. Technically difficult neuraxial techniques in asleep paralysed patients carry additional risks, especially when performed using landmarks [5]. In the presented case a potentially difficult spinal was rendered straightforward by the pre-procedure use of ultrasound imaging. If not for the serendipity of having a consultant present experienced in the use of ultrasound assisted neuraxial procedures this spinal was likely to require multiple attempts, increased time and may have been impossible for the operating anaesthetist.

Ultrasound has the potential to be an extremely useful tool in performing neuraxial procedures. It can be used to identify a safe level for needle insertion, to identify the midline, to estimate the depth of the spinal canal and show any longitudinal rotation of the spine. This can reduce time to successful dural puncture, improved patient satisfaction and reduced complication rate [6].

Intubation and extubation were identified as aerosol generating procedures and high risk for the spread of Covid-19 leading to a preference for regional anaesthesia over GA where possible [7,8]. At the time of this case it was recommended to wear full PPE when conducting general anaesthesia and staff were issued with either an FFP3 mask, a JSP Force 8 or Force 10 mask (JSP, Minster Lovell, UK). These masks provide protection, but they lead to increased communication difficulties. The PPE muffled voices and was uncomfortable to wear for a prolonged period making it difficult to concentrate. Despite this it was possible to impart the relevant information to render a difficult spinal straightforward.

Twenty years ago, central venous access and peripheral nerve blocks were all performed routinely without ultrasound. Many anaesthetists now consider ultrasound guidance to be mandatory in the performance of these procedures and this is reflected in national guidance. We argue that, with the increasing availability of ultrasound, anaesthetists should become more familiar using ultrasound when performing neuraxial techniques. In fact, National Institute for Health and Care Excellence guidance from 2008 advocates the use of ultrasound in locating the epidural space for catheterisation. Despite this the current curriculum from the Royal College of Anaesthetists in the UK does not mention the use of ultrasound guided neuraxial procedures. We suggest that ultrasound guided neuraxial should be taught early in anaesthetic training in order for trainees to develop experience with this skill in patients with ‘normal’ backs.

Acknowledgements

This case is from June 2020 and is published with the written consent of the patient.

Conflict of Interests

No external funding and no competing interests declared.

References

  1. Perlas A, Chaparro LE, Chin KJ (2016) Lumbar Neuraxial Ultrasound for Spinal and Epidural Anesthesia: A Systematic Review and Meta-Analysis. Regional Anesthesia and Pain Medicine 41: 251-260. [crossref]
  2. Park SK, Yoo S, Kim WH, Lim YJ, Bahk JH, et al. (2019) Ultrasound-assisted vs. landmark-guided paramedian spinal anaesthesia in the elderly: A randomised controlled trial. European Journal of Anaesthesiology 36: 763-771. [crossref]
  3. Park SK, Bae J, Yoo S, Kim WH, Lim YJ, et al. (2020) Ultrasound-Assisted Versus Landmark-Guided Spinal Anesthesia in Patients With Abnormal Spinal Anatomy: A Randomized Controlled Trial. Anesthesia and Analgesia 130: 787-795. [crossref]
  4. Kallidaikurichi SK, Iohom G, Loughnane F, Lee PJ (2015) Conventional Landmark-Guided Midline Versus Preprocedure Ultrasound-Guided Paramedian Techniques in Spinal Anesthesia. Anesthesia and Analgesia 121: 1089-1096. [crossref]
  5. Drasner K. (2004) Thoracic epidural anesthesia: asleep at the wheal? Anesth Analg 99: 578-9. [crossref]
  6. Perlas A (2010). Evidence for the Use of Ultrasound in Neuraxial Blocks. Regional Anesthesia & Pain Medicine 35: supp.43-46.
  7. Young B, Onwochei D , Desai N (2020) Conventional landmark palpation vs. preprocedural ultrasound for neuraxial analgesia and anaesthesia in obstetrics – a systematic review and meta‐analysis with trial sequential analyses. Anaesthesia.
  8. Uppal V, Sondekoppam RV, Landau R, El-Boghdadly K, Narouze S, et al. (2020) Neuraxial anaesthesia and peripheral nerve blocks during the COVID-19 pandemic: a literature review and practice recommendations. Anaesthesia 75: 1350-1363. [crossref]

Efficacy, Safety and Affordability Disparities of Gastrointestinal Cancer Changing Plans of Treatment of Cancer Patients

DOI: 10.31038/CST.2022713

Abstract

Purpose: With daily increase of GIT cancer incidence, there is more discovery of new regimens, raising the question: how much can cancer patient afford effective safe treatment?

Methods: Safety and efficacy grades version 2021 NCCN evidence-based blocks are used in this research, Egyptian population divided according to income in to 5 categories: Poorest (4860), poor (8460), middle (22800), rich (41100), richest (66583). We considered a medicine as affordable if 20% or less of monthly income is needed to cover monthly need of medicine. Affordability divided to 5 grades according to percentage of income needed to cover treatment: very inexpensive: ≤20%, inexpensive: 20-40%, moderately expensive 40-60%, expensive 60-80%, awfully expensive ≥ 80%. Binary logistic regression model was performed to assess affordability of cancer treatments in different cancer types using efficacy of regimen, safety of regimen, line of therapy, site of treatment and income class as predictors.

Results: Most GIT regimens are moderately effective 223 (51.6), while most regimens 277 (64.1) are mildly toxic. Minimally effective regimens increase the chance of being affordable by 15 times if compared to highly effective P<0.0001, moderately effective increase the chance of affordability by 3 times if compared to highly effective P<0.0001. Mildly toxic regimen increases the chance of affordability by 3 times if compared to occasionally toxic treatment. P=0.002. Adjuvant regimens have increased chance of affordability by 17 times if compared to second line.

Conclusion: GIT cancer patients have more treatment affordability for neo-adjuvant/adjuvant than other regimens first-line therapy is more affordable than other regimens for stage IV disease, highly effective regimens have the low affordability while mildly toxic regimens have more chance of affordability than other regimens with different safety categories.

Introduction

With the increase of gastrointestinal cancer global burden [1], there is also increase in number of approved drugs for cancer treatment, on the other hand, there is rapid raise of cancer therapy prices all over the world, with associated decrease cancer treatment affordability between cancer patients [2].

The decision of cancer treatment protocol by any committee depends on many factors, not only magnitude of patient benefit and safety of treatment but also affordability and access of treatment for patients [3].

Value based pricing of cancer treatment is one of the most common and important tools for reducing cancer medicine, by these tools we consider efficacy, toxicity, quality-of-life before pricing certain medication for cancer treatment [4]. National cancer comprehensive network NCCN blocks, European society of medica oncology-magnitude of clinical benefit ESMO-MCB and American society of clinical oncology value framework AVF are different stakeholders’ frameworks to help assess the value of oncology regimens [5,6].

Oncologists have different perspectives for affordability of cancer therapy in different regions, which result in different cost-efficacy of treatment [7]. Also, there is certain different relation between affordability and efficacy of different cancer treatment in different countries [8].

This article will address relation between affordability, efficacy, safety of GIT cancer therapy in EGYPT.

Methods

Safety and efficacy grades version 2021 NCCN evidence-based blocks are used as reference for safety and efficacy for treatment protocols.

Egyptian populations were divided according to average monthly income in to 5 categories by EGP: Poorest (4860), poor (8460), middle (22800), rich (41100), richest (66583).

We considered a medicine as affordable if 20% or less of monthly income is needed to cover monthly need of medicine.

Affordability divided to 5 grades according to percentage of income needed to cover treatment: very inexpensive: ≤20%, inexpensive: 20-40%, moderately expensive 40-60%, expensive 60-80%, awfully expensive ≥ 80% [9].

Local essential drug list and local drug pricing index are used as reference for cancer pricing of whole regimens with added pricing of supportive care and hospital admission.

Binary logistic regression model was performed to assess affordability of cancer treatments in different cancer types using efficacy of regimen, safety of regimen, line of therapy, site of treatment and income class as predictors and used to investigate the relation between efficacy and safety of regimens in different tumor sites.

Results

Numbers of Treatment Protocols for Each Tumor Site

A total of 432 treatment regimens from NCCN blocks N (%): Colon 166 (38.4), esophageal 88 (20.4), gastric 80 (18.5), pancreatic 70 (16.2) and HCC 28 (6.5) (Figure 1).

new fig 1

Figure 1: Affordability Grading by site of treatment and income class.

In colon cancer, the highest number of treatment protocols are in second line setting 41 (24.7), while protocols for adjuvant, first line, neoadjuvant, subsequent therapy and third line therapy, and primary treatment are showing the following N (%): 24 (14.5), 27 (16.3), 14 (8.4), 21 (12.7), 22 (13.3), 17 (10.2) respectively.

For esophageal and esophagogastric junction cancer, the number first line therapy for metastatic disease is the highest 39 (44.3), and third line/subsequent lines are the lowest 2 (2.3).

For gastric cancer first line for metastatic disease are the highest 36 (45%) and there is only one third line.

For HCC, most treatment protocols are for first line stage IV disease 18 (64.3), and for pancreatic adenocarcinoma most protocols are for first line 33 (47.1) (Table 1 and Figure 1).

Table 1: Affordability vs safety for each cancer treatment in the richest population.

table 1

Efficacy of Treatment Regimens

Most of GIT cancer regimens present in NCCN blocks, are moderately effective 223 (51.6), while none of them are highly effective, minimally effective regimens 60 (13.9), very effective regimens 149 (34.5).

While regimens for gastric cancer are very effective 39 (48.8), pancreatic adenocarcinoma accounts for the highest number of minimally effective regimens 22 (31.4).

Safety of Treatment Regimens

None of treatment regimens for GIT cancers has no toxicity, most of them are mildly toxic 277 (64.1).

Colon cancer account for the only highly toxic regimens 2 (1.2) in GIT cancer while HCC account for the highest number of mildly toxic regimens 24 (85%) (Tables 1, 2, Figures 2 and 3).

Table 2: Relation between efficacy and safety for each cancer site.

table 2
 

new fig 2

Figure 2: The relationship between efficacy of treatment and safety of treatment according to site of tumor.

new fig 3

Figure 3: Percentage and distribution of lines of treatment by tumor sites:

Affordability versus Efficacy of Treatment for Each Group of GIT Cancer Patients

While poorest patient has no affordability for any treatment for GIT cancer, poor: n (%) 7 (1.6), middle 49 (11.3), rich 110 (25.5) and richest has better affordability (Table 1 and Figure 2).

In colon cancer, 155 (93.4) of regimens are awfully expensive for poorest patient, 154 (92.8) for poor, 111 (66.9) for middle, 104 (62.7) for rich and 74 (44.6) for richest.

While esophageal cancer account for the only inexpensive regimens for poorest patient 4 (4.5), HCC account for the highest number of awfully expensive regimens for the richest group 14 (50).

There is significant negative relation between affordability and efficacy in middle, rich and income patient, which appear more in pancreatic cancer P<0.0001 and appear also in richest HCC P<0.0001.

Affordability versus Safety of Treatment for Each Cancer Patient Group

Most treatment regimens are not affordable for poorest and poor patients, but at the same time, there is positive week correlation between safety and affordability P<0.0001, appear most in colon and gastric poor patients.

For middle income patient with colon cancer, positive significant correlation occurs with P<0.0001, while in HCC there is negative moderately strong correlation P=0.01.

For rich group, the same correlation appears stronger and for richest patient it appears stronger P<0.0001 (Figure 2).

Results of the Use of Binary Logistic Regression Model for Relation between Affordability, Safety, and Efficacy

Binary logistic regression model was performed to assess Affordability of cancer treatments in different cancer types using efficacy of regimen, safety of regimen, quality of evidence, consistency of evidence, line of therapy, site of treatment and income class as predictors (Table 3 and Figure 3).

Table 3: Binary logistic regression model measuring affordability relation with efficacy and safety for all GIT cancer sites

table 3

The calculated quality measures showed good quality of fit for the established model were the r square = 0.550 and Hosmer Lemeshow test revealed p=0.389.

All predictors in the Model were clinically significant except quality of evidence and consistency of evidence.

The model showed that the minimally effective regimen has increased the chance of being affordable regimen by 15 times if compared to highly effective treatment (OR=14.724, P<0.0001), while at the same time, the moderately effective drug increases the chance of affordability t by 3 times if compared to highly effective treatment (OR=3.40, P<0.0001).

As for safety of regimen, the model shows that being a mildly toxic drug increase the chance of being affordable regimen by 3 times if compared to occasionally toxic regimen (OR=2.613, P=0.002), however, highly toxic, and moderately toxic regimens did not show any difference in affordability if compared to occasionally toxic (P=0.999 and P=0.506 respectively).

As for line of therapy, the model shows that Neoadjuvant/Adjuvant regimens has increased the chance of being affordable treatment by 17 times if compared to Second line/subsequent treatment (OR=17.428, P<0.0001), while the first line treatment has increased chance of being affordable treatment by 3 times if compared to Second line/subsequent treatment (OR=3.497, P<0.0001).

As for population income, patients from middle class increase the chance of being affordability for treatment by 20 times if compared to the poor/poorest class (OR=20.589, p<0.0001), rich class increase the chance of being Affordable treatment by 74 times if compared to the poor/poorest class (OR=74.173, p<0.0001),finally patients in richest class increase the chance of their affordability for treatment by more than 200 times if compared to the poor/poorest class (OR=275.753, p<0.0001).

Finally, for site of treatment, the model shows that Esophageal cancer treatment regimens has increased chance of being affordable by 2 times if compared to Colon cancer (OR=2.515 , P<0.0001), while gastric cancer has increased chance of being affordable by 3 times if compared to Colon cancer (OR=3.733, P<0.0001), Pancreatic cancer has the increased chance of being affordable by 6 times if compared to Colon cancer (OR=6.202, P<0.0001), however hepatocellular carcinoma did not show any difference in affordability if compared to colon cancer.

The Results of Relation between Efficacy and Safety

In total sample, the relationship between efficacy and safety is negative and weak, (-0.152, p-value < 0.01), which means that as the treatment becomes more effective, it is supposed to become less toxic but in weak manner as the value of correlation coefficient is 0.152 less than 0.3 which is the cutoff point of weak correlation (Table 1 and Figure 2).

For colon cancer, esophageal and esophagogastric junction cancer, the correlation between safety and efficacy is negative and weak, (-0.091 and -0.149 respectively), but for Pancreatic Adenocarcinoma, the correlation is negative moderate (-0.359). On the contrary, only for Hepatocellular carcinoma, the correlation between safety and efficacy is positive and strong (0.653).

Discussion

Our study confirmed that not all economy levels of patients with GIT cancer can afford for effective safe treatment, raising the needs for insurance and help from sponsors in most levels of social classes, at the same time, there is significant negative relation between efficacy and affordability for GIT cancer therapy.

Our explanation for this relation is that, when we need to increase efficacy for cancer therapy, we add another chemotherapy, which dose not only add to treatment price and efficacy, but it also decreases safety of cancer treatment.

Another way for increase efficacy is to add immunotherapy or targeted therapy, which are both expensive for most of patient income groups in the study.

Our study also concluded that treatment of early stages of cancer are more affordable than late stages, which will encourage governments to add more efforts for early detection of GIT cancer which will not only save lives but also will save money.

Treatment of some cancer sites like esophagus and stomach are more affordable than others like colon, this may be because investment in common cancers like colon cancer are more common, which increase price of treatment these cancers.

For poor and poorest patients, our recommendation is to do more screening for early detection of cancer in these groups and on the other hand, using bio similar treatment with lower prices may be of benefit.

According to recent salary survey [9], more than 75% of Egyptian population needs support from insurance for GIT cancer therapy as their monthly income is less than 44000 EGP, which directed governmental plans to invest more in screening and early detection of cancer.

Considering the common GIT cancer in Egypt like HCC, which has the least affordability for richest population in advanced stages according to our results, detection in early stages will be having greatest benefit for survival, more than late stages.

According to our results, relation between efficacy and safety is positive and strong for HCC, very effective regimens and moderately effective regimens are mildly toxic, while minimally effective regimens are moderately toxic, most of these lines of systemic therapy are for first line advanced disease, with low survival benefit.

References

  1. Arnold, Melina, Christian C. Abnet, Rachel E. Neale, Jerome Vignat, Edward L. Giovannucci, et al. (2020) Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159: 335-349. [crossref]
  2. Cortes, Javier, Jose Manuel Perez‐García, Antonio Llombart‐Cussac, Giuseppe Curigliano, et al. (2020) Enhancing global access to cancer medicines. CA: a cancer journal for clinicians 70: 105-124. [crossref]
  3. Shulman, Lawrence N., Claire M. Wagner, Ronald Barr, et al. (2016) Proposing essential medicines to treat cancer: methodologies, processes, and outcomes. Journal of Clinical Oncology 34: 69. [crossref]
  4. Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R (2017) Do patient access schemes for high-cost cancer drugs deliver value to society? Lessons from the NHS Cancer Drugs Fund. Ann Oncol 28:1738-1750. [crossref]
  5. Cherny, Nathan I., Richard Sullivan, Urania Dafni, J. Martijn Kerst, et al. (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology 26: 1547-1573.
  6. Shah-Manek, Bijal, Joseph S. Galanto, Huong Nguyen, and Robert Ignoffo (2017) Value frameworks for the patient-provider interaction: a comparison of the ASCO value framework versus NCCN evidence blocks in determining value in oncology. Journal of Managed Care & Specialty Pharmacy 23: S13-S20.
  7. Shah-Manek, Bijal, William Wong, Arliene Ravelo, and Marco DiBonaventura (2018) Oncologists’ perceptions of drug affordability using NCCN evidence blocks results from a national survey. Journal of Managed Care & Specialty Pharmacy 24: 565-571.
  8. Salas-Vega, Sebastian, Emily Shearer, and Elias Mossialos (2020) Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Social Science & Medicine 258: 113042. [crossref]
  9. http://www.salaryexplorer.com/salary-survey.php?loc=64&loctype=1#disabled
  10. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, et al. (2016) Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 2;387(10013):61-9. [crossref]

Growth Hormone Secretagogue Peptide-6 Modulates Antimicrobial Activities in Tilapia (Oreochromis sp.) Challenged with Edwardsiella tarda

DOI: 10.31038/AFS.2021354

Introduction

Edwardsiella tarda is one of the most significant bacterial pathogens to fish aquaculture. This Gram-negative, intracellular bacterium is the causal agent of the “edwardsiellosis” which cause generalized septicemia and lesions on internal organs. It has been reported worldwide in economically important fish species, including Japanese eel (Anguilla japonica), red sea bream (Pagrus major), yellowtail (Seriola quinqueradiata), channel catfish (Ictalurus punctatus), turbot (Scophthalmus maximus) and tilapia (Oreochromis sp.) [1,2]. This infection leads to enormous economic losses in cultured seawater and freshwater fish [1].

Different strategies have been attempted to treat and prevent E. tarda infections, including antibiotics and chemicals. However, overuse or abuse of these can result in the selection and development of drug resistant pathogens [3,4]. As a promising alternative, immunostimulants may represent a safe and effective treatment to enhance an antimicrobial response for preventing fish infection by a wide range of pathogens.

Synthetic growth hormone (GH) secretagogues (GHSs) consist of a family of ligands, initially termed GH-releasing peptides (GHRPs) [5] which are recognized by the GHS receptor (GHS-R). GHS-R is expressed predominantly in the brain and pituitary gland, and in immune system cells from mammals and fish, suggesting a relation between ligands for these receptors and the immune system [6]. Growth Hormone-Releasing Peptide 6 (GHRP-6) is a six amino acid synthetic peptide with demonstrated stimulatory effects on innate and adaptive immune system in teleost fish [7,8]. The aim of this study was to assess the antimicrobial effects of GHRP-6 against bacterial infection in tilapia, as well as to measure gene expression of some immune-related genes before and after E. tarda infection.

Materials and Methods

Fish and Peptide Source

Juvenile tilapias (Oreochromis niloticus, male, ~100 g) were obtained from the Aquaculture Research Station at the Center for the Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. Fish were kept alive in aerated freshwater in 120 L tanks under a 12 h light: 12 h dark photoperiod. They were fed commercial dry diet for fish (CENPALAB, Habana, Cuba). Water temperature was maintained at 26-28°C. Fish were acclimated for one week before each experiment. All animal experiments were previously approved by the Ethics Committee of the Center for Genetic Engineering and Biotechnology, Havana, Cuba. The described work has been carried out in accordance with EU Directive 2010/63/EU for animal experiments.

GHRP-6 (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2, MW = 872.44 Da) with a purity > 99% was provided by Sigma-Aldrich, USA.

Fish Treatment with GHRP-6

Fish (26 tilapias per group) were injected by intraperitoneal route (i.p) during 7 days. One group of tilapias received GHRP-6 (0.2 µg/body weight (bwg)) in a total volume of 100 µL of PBS. The Control group was injected with the same volume of PBS. The dose employed for GHRP-6 was chosen based in previous experiments performed in the laboratory [9]. Spleen samples (n=6) were taken at 24 and 48 hours after the last injection. Tissue samples were stored in Ambion RNAlater (AppliedBiosystems, USA) at -20°C until use for RNA isolation.

Also, at 48 hours after the last peptide injection, a challenge was performed using an E. tarda strain by immersion bath as previously described by [10], with minor adjustments. Edwardsiella tarda strain was obtained from glycerol stock cultures stored at -80°C. Briefly, Nile tilapia juveniles (n=13 per group) were exposed to 108 CFU/mL of E. tarda (diluted in sterile PBS) by immersion bath during 1 h in a total volume of 40 L with aeration. After immersion bath, both groups were moved to 250 L aerated freshwater tanks in an isolated water flow system and kept in those conditions until sampling of gills and spleen (8 fish per group). The rest of the animals were daily checked until day 5th day when mortality started to occur. Two additional tanks with fish (n=7 per group: PBS and GHRP-6) were used as non-challenge controls of mortality. After the challenge concluded, waste water was treated with chlorine to avoid the releasing of live bacteria.

Spleen was sampled at 24 and 48 hours after challenge (hac) for gene expression analysis, as described above. To evaluate the antimicrobial effects of GHRP-6 on gills, samples were taken at 48 hours after the challenge (hac), under aseptic conditions and washed in 1 mL of 0.9% NaCl. Afterwards, this wash was serially diluted in sterile PBS, plated in tryptic soy agar (TSA) (Merck) and grown overnight at 37°C. The identity of the colonies grown in specific culture medium was confirmed by an API20E test (Biomérieux) and Gram staining.

Gene Expression Analysis

Tissue samples were processed on a Tissue Lyser unit (Qiagen, Hilden, Germany), extracting total RNA with RNeasy® Plus (QIAGEN GmbH, Germany) using the Quiacube platform. RNA purity and yield were determined using a NanoDrop Spectro-photometer (NanoDrop Technologies, USA). First-strand complementary DNA (cDNA) was synthesized from 1 μg total RNA using Superscript III First-Strand Synthesis Supermix for RT-PCR (Invitrogen Technologies, Carlsbad, California, USA) following fabricant ́s instructions.

Transcripts levels in the sampled organs were assessed by qPCR analysis. Gene’s sequences were obtained from the US National Center for Biotechnology Information database (NCBI). Specific primers were designed, using the web application Primer3 [11]. Each experimental sample was run in triplicate on 96-well plates and qPCR reactions were completed on the LightCycler® 480 II (Roche). All PCR reactions were of 20 µL volume and contained: 10 µL of LightCycler® 480 SYBR Green I Master 2x (Roche, Germany), 300 nM each primer (10 pmol/µL) and 4 µL of cDNA (50 ng/µL diluted 1:25 in RNase free water). For each plate, triplicate wells of a calibrator and RNA only control were also present. The program used for all qPCR reactions was as follows: pre-incubation at 95°C for 5 min followed by 50 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 30 s and extension at 72°C for 30 s. A melting curve was completed for every run from 72 to 95°C with a read every 5 s. Product specificity was determined through single PCR melting peaks. All qPCR data was analyzed using REST 2009 v2.0.13 [12]. Differences were expressed as fold changes. Gene expression was normalized to the references genes EF-1α and β-actin.

Statistical Analysis

The effects of GHRP-6 on the number of CFU in gills, was assessed using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA). The normal distribution of data was analyzed with D’Agostino Pearson’s test and the variance homogeneity with Bartlett’s test. A Student’s t parametric test was performed as data followed normal distribution for comparisons in each time point. For qPCR analysis, reactions efficiency was calculated using LinReg software and data were analyzed using REST 2009 software v2.0.13 [12,13]. This software calculates the relative expression to a control condition after normalize with the efficiency of the selected references genes. Differences were expressed as fold changes relative to Control group. A significance level of 0.05 was used for all analyses.

Results

After the last peptide injection with GHRP-6, the transcripts levels of IL-1β relative to Control group were up-regulated in spleen both at 24 (2.37 ± 0.58) and 48 (2.27 ± 1.64) hours. Also, Oreochromicin III was significantly up-regulated at 48 hours after treatment (5.99 ± 3.48). However, no significant differences were observed for Oreochromicins I and II and Granzyme transcripts (Figure 1).

fig 1

Figure 1: Gene expression analysis in spleen of tilapia (Oreochromis sp.) after treatment with GHRP-6 during seven consecutive days by i.p injection. Samples were taken at 24 and 48 hours after the last peptide injection. Fold change (FC) with respect to Control group were calculated by REST 2009 (FC>1 up-regulated; FC<1 down-regulated) and were expressed as mean ± SD (n=6). The asterisks indicate statistically significant differences relative to Control group, *(p < 0.05).

Once confirmed the positive modulation of a pro-inflammatory cytokine and an antimicrobial peptide in spleen, we evaluated the antimicrobial effect promoted by GHRP-6 after a challenge trial with E. tarda. With this aim, fish were challenged 48 hours after the peptide treatment with an E. tarda strain. Spleen samples were collected at 24 and 48 hours after challenge, while gills washes and were taken at 48 hours.

GHRP-6 treatment exerts a differential modulation over Oreochromicins, Granzyme and IL-1β mRNA expression profiles in spleen after E. tarda infection. Oreochromicin I was up-regulated (7.49 ± 3.32) at 48 hours, while, Oreochromicins II and III were down-regulated at 24 hours (0.12 ± 0.17 and 0.09 ± 0.07, respectively). On the other hand, IL-1β was statistically down-regulated (0.067 ± 0.002) at 48 hours (Figure 2).

fig 2

Figure 2: Gene expression analysis in spleen of tilapia (Oreochromis sp.) after treatment with GHRP-6 (during 7 consecutive days by i.p injection) and challenge with an Edwardsiella tarda strain. Twenty-four and 48 hours after the last peptide injection, fish from Control and GHRP-6 treated groups (13 fish per group) were exposed for one hour to 1 × 108 CFU/mL of E. tarda by immersion bath. Gene transcription was analyzed by qPCR in spleen sampled at 24 and 48 h after challenge. Fold change (FC) with respect to Control group were calculated by REST 2009 (FC>1 up-regulated; FC<1 down-regulated) and were expressed as mean ± SD (n=8). The asterisks indicate statistically significant differences relative to Control group, *(p < 0.05), **(p < 0.01) and ***(p < 0.001).

In gills washes, there were statistically significant lower CFU/mL of bacteria in group treated with GHRP-6 (6.8 x 104 ± 8.6 x 103 CFU/mL) compared to the Control group (3.9 x 105 ± 6.4 x 104 CFU/mL) (Figure 3). We observed clinical signs of the disease in some animals of the Control group such as loss of pigmentation and petechial hemorrhage in fin and skin, aspects reviewed by [1] as evidence of the infection. We started to observed mortality in Control group of infected fish since the 5th day, being 4/7 in Control group and 0/7 in GHRP-6 treated group.

fig 3

Figure 3: Gills’ bacterial load in Control and GHRP-6 treated groups after treatment with GHRP-6 (during 7 consecutive days by i.p injection) and challenge with an Edwardsiella tarda strain. Forty-eight hours after the last peptide injection, fish from Control and GHRP-6 treated groups (13 fish per group) were exposed for one hour to 1 × 108 CFU/mL of E. tarda by immersion bath. Total number of CFU/mL in gills washes were counted at 48 h after challenge. Data represent the mean ± SD (n=8) of three independent experiments. The analysis of data was performed using a Student’s t test. The asterisks represent statistically significant differences between groups, *(p < 0.05).

Discussion

Edwardsiella tarda is a Gram-negative intracellular pathogen which causes enormous economic losses in cultured seawater and freshwater fish [14]. Infection by E. tarda may produce severe lesions in internal organs such as spleen [15-17]. Gills constitutes one of the entry routes of E. tarda infections in fish [18], thus, the use of immunostimulants with antimicrobial effects for preventing infestations could be promising.

Previously, it has been demonstrated that GHRP-6 is a growth hormone secretagogue that improve different innate and adaptive immune system parameters in aquatic organisms [7,8,19]. More recently, we provided new evidence of a direct link between GHRP-6 treatment and enhanced antimicrobial peptides transcription in tilapia [20]. In this study we shed light over the effect of this peptide as stimulator of the antimicrobial immune response in tilapia with and without the presence of a challenge with E. tarda.

Spleen constitutes one of the major lymphoid tissues in fish and also is affected by the infection with bacterial pathogens, such as E. tarda [21]. GHRP-6 statistically up-regulated the mRNA levels of IL-1β in tilapia spleen. Our results are in agreement with previous studies where IL-1β was up-regulated after the administration of immunostimulants [22,23].This cytokine is a critical mediator of the inflammatory response against microbial invasion and can stimulate the immune response by activating lymphocytes or by inducing the release of other cytokines capable of triggering macrophages, NK cells and lymphocytes (Yuan et al., 2008; [18,24]. Also, Oreochromicin III was up-regulated after the treatment with the GHS. Previous studies have demonstrated that this antimicrobial peptide has immunomodulatory effect in mammals. Oreoch III stimulated the release of IFN-γ from mice splenocytes [25].

In the current study, Oreochromicins I, II and III were differentially regulated by GHRP-6 in spleen after the challenge with E. tarda. Therefore, Oreochromicins could be involved in the elimination of this pathogen in tilapia spleen and other tissues. These antimicrobial peptides belong to the piscidin-like family and are expressed in different cell types such as neutrophils, granular eosinophils, monocytes and macrophages [26]. [27] demonstrated strong antimicrobial activity of Oreochromicin II against E. tarda in vitro. Recent studies revealed that GHRP-6 stimulates the antimicrobial immune response against Pseudomonas aeruginosa in tilapia and up-regulated the transcription of Oreochromicins as well in the presence of this pathogen [20].

Our results revealed that the treatment with GHRP-6 statistically decreased the bacterial load of E. tarda in gills washes 48 hours after the challenge as we observed a significant up-regulation of the mRNA levels of Oreochromicin I in spleen. Fish´s gills possess different cells populations and a mucus layer associated to it, which contains different antimicrobial molecules that contribute to the bacterial clearance [28,29]. The obtained results suggested that GHRP-6 may stimulate the antimicrobial response which limits the growth of the bacteria in gills, and thus could restrict the bacterial infection. Previous reports have shown that AMPs can protect against infections by E. tarda in fish [30]. Further studies will be conducted in order to gain knowledge at the histological level. In addition, after the challenge, we observed a down-regulation of IL-1β. Previous studies have demonstrated that when the expression of this cytokine decreases significantly at 48 hours, it is possible that this has increased within a few hours of completing the challenge. For example, [31], showed that in a challenge with Aeromonas salmonicida by intraperitoneal injection, IL-1β levels in spleen were up-regulated at 2 and 6 hours after the infection, but at 24 hours did not showed significant differences. Moreover, in a challenge carried out with E. tarda by intramuscular injection, an increase in IL-1β expression was obtained at 6 and 24 hours, in animals previously immunized with the flagellar protein FlgD by intramuscular injection [32-34].

The results of this trial suggest that the induction of IL-1β could be transient and that other effector components of innate immunity are participating in the protection of the organism. Various authors showed that when the expression of this cytokine decreases significantly at 48 hours, it is possible that this has increased within a few hours of completing the challenge.

In summary, our results suggested novel roles of GHRP-6 in tilapia as possible immunostimulant, which is able to promote the antimicrobial activity against some Gram-negative intracellular bacterial infections, such as E. tarda. Currently we are planning to evaluate the protective effect of this GHS at the histological level when administered in the presence of pathological bacteria such as E. tarda. Also, we are developing an oral formulation in order to evaluate its immunostimulant effects in long term experiments as part of the diet and its effects on guts bacterial load after a bacterial challenge. These studies will allow us to gain a deeper knowledge about the molecular basis of GHRP-6 mechanism in relation with antibacterial response in fish for its potential application in aquaculture.

Author Contributions

LH performed majority of experiments, contributed to experimental design, wrote the first draft and reviewed the final version of the manuscript. HC, ANR, DP, AM, LB, FH, OR, SP contributed with the development of the experiments. JV contributed with the development of the experiments and reviewed the final version of the manuscript. ME, contributed to experimental design and reviewed the final version of the manuscript. RM contributed to experimental design, wrote the first draft of the manuscript and reviewed the final version of the manuscript.

Data Availability

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Keywords

GHRP-6, Antimicrobial activity, Edwardsiella tarda, Tilapia

References

  1. Park Bin S, Aoki T, Jung TS (2012) Pathogenesis of and strategies for preventing Edwardsiella tarda infection in fish. Veterinary Research 43: 1-11.
  2. Baba E, Acar Ü, Öntaş C, Kesbiç OS, Yılmaz S (2016) Evaluation of Citrus limon peels essential oil on growth performance, immune response of Mozambique tilapia Oreochromis mossambicus challenged with Edwardsiella tarda. Aquaculture 465: 13-18.
  3. Cha YJ, Lee CR., Kwon JY, Kang YJ (2017) Protective effects of CpG-ODN 2007 administration against Edwardsiella tarda infection in olive flounder (Paralichthys olivaceus). Fish and Shellfish Immunology 68: 327-331. [crossref]
  4. Na-Phatthalung P, Teles M, Voravuthikunchai SP, Tort L, Fierro-Castro C (2018) Immune-related gene expression and physiological responses in rainbow trout (Oncorhynchus mykiss) after intraperitoneal administration of Rhodomyrtus tomentosa leaf extract: A potent phytoimmunostimulant. Fish and Shellfish Immunology 77: 429-437. [crossref]
  5. Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, et al. (1981) Design, Synthesis, and Biological Activity of Peptides which Release Growth Hormone in Vitro. Endocrinology 108: 31-39.
  6. Hattori N (2009) Growth Hormone & IGF Research Expression, regulation and biological actions of growth hormone ( GH ) and ghrelin in the immune system. Growth Hormone & IGF Research 19: 187-197. [crossref]
  7. Martinez R, Carpio Y, Morales A, Lugo JM, Herrera F, et al. (2016a) Oral administration of the growth hormone secretagogue-6 (GHRP-6) enhances growth and non-specific immune responses in tilapia (Oreochromis sp.). Aquaculture 452: 304-310.
  8. Martínez R, Hernández L, Gil L, Carpio Y, Morales A, et al. (2017a) Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus). Vaccine 35: 5722-5728. [crossref]
  9. Martinez R, Núñez de Villavicencio-Díaz T, Sánchez A, Noda J, Gil L, et al. (2016b) Comparative proteomics analysis of growth hormone secretagogue A233 treatment effect in J774A.2 murine macrophages cells. Biochem Biophys Rep 5: 379-387. [crossref]
  10. Velázquez J, Acosta J, Herrera N, Morales A, González O, et al. (2017) Novel IFNγ homologue identified in Nile tilapia (Oreochromis niloticus) links with immune response in gills under different stimuli. Fish and Shellfish Immunology 71: 275-285. [crossref]
  11. Rozen S, Skaletsky H (2000) Primer3. Methods Mol Biol 132: 365-386.
  12. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Research 30: 36. [crossref]
  13. Camacho-Rodiguez H, Guillén-Pérez IA, Roca-Campaña J, Baldomero-Hernández JE, Tuero-Iglesias, et al. (2018) Heberprot-P´s Effect on Gene Expression in Healing Diabetic Foot Ulcers. MEDICC Review 20: 10-14. [crossref]
  14. Mohanty BR, Sahoo PK (2010) Immune responses and expression profiles of some immune-related genes in Indian major carp, Labeo rohita to Edwardsiella tarda infection. Fish and Shellfish Immunology 28: 613-621. [crossref]
  15. Mohanty BR, Sahoo PK (2007) Edwardsiellosis in fish: a brief review. Journal of Biosciences 32: 1331-1344. [crossref]
  16. Zhou Z, Sun L (2016) Edwardsiella tarda-Induced Inhibition of Apoptosis: A Strategy for Intracellular Survival. Frontiers in Cellular and Infection Microbiology 6: 76. [crossref]
  17. Lee W, Ahn G, Young J, Min S, Kang N, et al. (2016) A prebiotic effect of Ecklonia cava on the growth and mortality of olive flounder infected with pathogenic bacteria. Fish and Shellfish Immunology 51: 313-320. [crossref]
  18. Pressley ME, Phelan PE, Eckhard Witten P, Mellon MT, Kim CH (2005) Pathogenesis and inflammatory response to Edwardsiella tarda infection in the zebrafish. Developmental and Comparative Immunology 29: 501-513. [crossref]
  19. Martínez R, Carpio Y, Arenal A, Lugo JM, Morales R, et al. (2017b) Significant improvement of shrimp growth performance by growth hormone-releasing peptide-6 immersion treatments. Aquaculture Research 48: 4632-4645.
  20. Hernández L, Camacho H, Nuñez-Robainas A, Palenzuela DO, Morales A, et al. (2021) Growth hormone secretagogue peptide-6 enhances oreochromicins transcription and antimicrobial activity in tilapia (Oreochromis sp.). Fish and Shellfish Immunology 119: 508-515. [crossref]
  21. Velázquez J, Acosta J, Lugo JM, Reyes E, Herrera F, et al. (2018) Discovery of immunoglobulin T in Nile tilapia (Oreochromis niloticus): A potential molecular marker to understand mucosal immunity in this species. Developmental and Comparative Immunology 88: 124-136. [crossref]
  22. Nootash S, Sheikhzadeh N, Baradaran B, Oushani AK, Maleki Moghadam MR, et al. (2013) Green tea (Camellia sinensis) administration induces expression of immune relevant genes and biochemical parameters in rainbow trout (Oncorhynchus mykiss). Fish and Shellfish Immunology 35: 1916-1923. [crossref]
  23. Huang X, Hu B, Yang X, Gong L, Tan J, et al. (2019) The putative mature peptide of piscidin-1 modulates global transcriptional profile and proliferation of splenic lymphocytes in orange-spotted grouper (Epinephelus coioides). Fish and Shellfish Immunology 86: 1035-1043. [crossref]
  24. Mehrabi Z, Firouzbakhsh F, Rahimi-Mianji G, Paknejad H (2019) Immunostimulatory effect of Aloe vera (Aloe barbadensis) on non-specific immune response, immune gene expression, and experimental challenge with Saprolegnia parasitica in rainbow trout (Oncorhynchus mykiss). Aquaculture 503: 330-338.
  25. Acosta J, Carpio Y, Valdés I, Velázquez J, Zamora Y, et al. (2014) Co-administration of tilapia alpha-helical antimicrobial peptides with subunit antigens boost immunogenicity in mice and tilapia (Oreochromis niloticus). Vaccine 32(2): 223-229. [crossref]
  26. Valero Y, Saraiva-fraga M, Guardiola FA (2018) Antimicrobial peptides from fish : beyond the fight against pathogens. Reviews in Aquaculture 12: 1-30.
  27. Acosta J, Montero V, Carpio Y, Velázquez J, Garay HE, et al. (2013) Cloning and functional characterization of three novel antimicrobial peptides from tilapia (Oreochromis niloticus). Aquaculture 372-375: 9-18.
  28. Koppang EO, Kvellestad A, Fischer U (2015) Mucosal Health in Aquaculture Fish mucosal immunity: gill. In Mucosal Health in Aquaculture. Elsevier.
  29. Cabillon N, Lazado C (2019) Mucosal Barrier Functions of Fish under Changing Environmental Conditions. Fishes 4: 2.
  30. Liang Y, Guan R, Huang W, Xu T (2011) Isolation and identification of a novel inducible antibacterial peptide from the skin mucus of Japanese Eel, Anguilla japonica. Protein Journal 30: 413-421. [crossref]
  31. Feng CY, Johnson SC, Hori TS, Rise M, Hall JR, et al. (2009) Identification and analysis of differentially expressed genes in immune tissues of Atlantic cod stimulated with formalin-killed, atypical Aeromonas salmonicida. Genomics 37: 149-163. [crossref]
  32. Zhang M, Wu H, Li X, Yang M, Chen T, et al. (2012) Edwardsiella tarda flagellar protein FlgD: A protective immunogen against edwardsiellosis. Vaccine 30: 3849-3856. [crossref]
  33. Costa AA, Leef MJ, Bridle AR, Carson J, Nowak BF (2011) Effect of vaccination against yersiniosis on the relative percent survival, bactericidal and lysozyme response of Atlantic salmon, Salmo salar. Aquaculture 315: 201-206.
  34. Xu T, Zhang XH (2014) Edwardsiella tarda: An intriguing problem in aquaculture. Aquaculture 431: 129-135.

The Effectiveness of Topical Metronidazole Management for Malignant Fungating Wound Odor: Nursing Perspective

DOI: 10.31038/CST.2022712

Abstract

Objectives: Malignant fungating wounds (MFW) defined as a wound that arise when cancerous cells invade the skin and metastasis to the surrounding blood and lymph vessel [1], Malignant wounds, also known as fungating tumors, tumor necrosis, ulcerative malignant wounds, or fungating malignant wound [2]. Moreover, The prevalence of MFW is (5-10%) of patient who suffer from metastasis tumors, it’s happened in age between 60-70 years during last 6 months, the MFW effect on this area of body: Breast (62%), Head and Face (24%), Groin and Genitals (3%), Back (3%), and other (8%) [3]. MFW effect on both a physical and psychological for the patient, caregiver, and clinician. These wounds are often associated with pain, odor, bleeding, and an unpleasant appearance. The goals in the care of patients with malignant wounds include managing wound exudate, odor, bleeding and pain, preventing infection, and promoting the emotional wellbeing of the patient and family [4]. The purpose of this study to evaluate topical metronidazole management of MFW odor.

Methods: A search using search engines such as PubMed and Google scholar were used in finding articles related to the review topic.

Key findings: This review highlighted the malignant fungating wounds (MFW) are uncommon [5] but create major challenges for nurses concerned in cancer care [6]. Patient felt socially isolated because he or she embarrassed from odor and leakage at the wound site, needs to change dressing and clothes constantly, so became low self-confidence to interact with others, change relationship with friends and even didn’t like to see wound for their families to keep good impression in their mind about her or his self. Represent the worst part of the patient’s cancer; live in a body that cannot be trust, therefore become isolation considering that wound-related stigma. It’s not only effect on patient well-being but as well effect on all dimensions of quality of life for their families. There both a physical and an emotional challenge for the patient, caregiver, and clinician.

Conclusions: Topical metronidazole has spread use in clinical practice around the world; it is inexpensive, easy to use, and easily available. Despite the lack of clinical studies to support the use of topical metronidazole in treatment of malodor MFW. Perhaps the lack of data is due to the fact that many studies are conducted with terminal patients or that fungating wounds are relatively rare. Although this review did not find strong scientific evidence supporting the efficacy of topical metronidazole in control of malodor MFW through randomized clinical studies, this review provides the best available evidence to support the use of topical metronidazole in the treatment of patients with malodor MFWs. Health care provider can use topical metronidazole to manage malodor MFW, but additional researches in this area is still necessary.

Keywords

Malignant wound, Metronidazole, Fungating, Malodor

Introduction

Fungating wound complications result from disturb of blood and lymph vessels, causes hypoxia, edema and necrosis, so the patient suffer from Pain (31.2%), followed by exudate (14.6%), odor (10.4%), itching (5.2%), bleeding (4.2%) [7], these symptoms MFWs often cause physical and psychological and social distress for the patients and their health care provider especially malodor, so patient with MFW feel embarrassment, and social isolation [8]. These malodor caused by the presence of necrotic tissue which is an ideal media for both aerobic and anaerobic bacteria, but mainly anaerobic bacteria that produce volatile fatty acids as a metabolic end product [9], this foul odor can cause gagging and vomiting and loss of appetite [10]. Exudate has a contributing factor to produce this malodor.

The Management of MFW is complex and challenging for health professionals especially control malodor [11]. Although there are multiple choices of dressings available to manage MFW odor, but suitable dressings to manage the odor still presents a challenge, therefore conduction of this review is to evaluate topical metronidazole management for MFW odor.

In order to inspect the knowledge related to topical metronidazole for MFW odor management among cancer patients, holistic and comprehensive review were conducted using the electronic databases of CINAHL, Pub Med, and Medline included for articles published between 1990 and 2015.

Malignant Wound Management

After reading the title and abstract, lists of 29 articles were considered. After that we chose the articles which investigated topical metronidazole for MFW odor management among cancer patients. Although fungating wounds pose a challenge for patients and caregivers, there are limited researches articles have been published on this topic [12]. Only 6 research articles were included in this review. The 6 articles published from 1992 to 2014 were selected and formed the basis for this review. The initial study included was published in 1992, with most studies published in 2014. These paper were published in nursing and Medical journals.

The 6 studies that build this review were quantitative research-based studies. 4 studies were randomized clinical trial studies, one study was descriptive cross-sectional studies, and one study was systematic review study. This systematic review included 1 randomized clinical trial study, 3 uncontrolled clinical trial studies, 1 case series study and 5 case report studies. Although only 6 studies were included in this research review, In the 6 studies a wide variety of designs, tools, and sample sizes were used.

MFW odor management remains insufficiently treated worldwide and still uncontrolled by evidence [13]. Until now approach regarding the most effective management protocol for patients with malodorous MFW is lacking [14]. However, based on this review topical metronidazole benefited patients with MFW, relieving them from their distressing malodor without fear of adverse reactions can be concluded.

The Effectiveness of Metronidazole in Wound Care Management

Metronidazole (Flagel) is a synthetic drug in the pharmacologic drug class Nitroimidazole. It prevents replication of bacteria by binding to their DNA [15]. It is an antibiotic agent used topically for reduction of malodor and is particularly effective for anaerobic bacteria and protozoa. While used widely there are variations in the concentrations used and the methods of application [16]. Numerous reports support its effectiveness in relieving malodor often within only a few days [17]. However topical Metronidazole may become ineffective when diluted by large amounts of exudates [18].

Topical metronidazole gel applied directly to the wound surface once or twice daily following cleansing, it is effective in the elimination or substantial reduction of malodor. Studies show it is usually effective within 2-3 days [19]. The moist environment produced by the gel may also help to promote wound debridement by facilitating autolysis of slough and necrotic tissue Metronidazole gel has been shown to be the best evidence-based practice for odour control. However, prolonged usage of antibiotics can become ineffective due to drug resistance.

Grocott P [20] argued that in large, heavily exuding wounds, topical application of gel might be ineffective as it becomes diluted by the exudate, the gel being absorbed by the dressings, whether the gel can penetrate deep enough into the necrotic tissue and the size of the wound may limit its efficacy. Also he argued that how the dose of topically applied gel is calculated, and recommend that more research is needed to support its use.

A double-blind placebo-controlled trial was conducted [21] to assess the value of topical metronidazole gel preparation in the palliation of the offensive odor of fungating tumors. During 11 days 9 patients with malodorous MFW were randomized into either control group 5 patients or treatment group topical Metronidazole gel 4 patients. Subjective odor assessments were performed by both patients and medical staff. This experiment confirms the efficacy of 0.8% metronidazole gel in reducing the odor associated with open fungating tumors without adverse effects. Recommendations from Bower et al for the control of malodor were daily wound cleansing and dressing for 7 days, followed by a 5-day course of metronidazole gel applied once daily at a dose of 1 g/cm2.

Others studied [22] the use of topical metronidazole gel on 47 patients, and found a decrease in malodor in 95% of patients by day 14. Anaerobic infection was eliminated in 84% of patients. However, estimated that the cost of topical metronidazole was 10 times the cost of tablets. A significant reduction in pain, exudate and cellulites with the use of topical metronidazole also recorded.

Kuge et al. [23] conducted a microbiological assessment and measured sensitivity to metronidazole gel 0.8% in 5 female breast cancer patients with fungating wound. In this uncontrolled clinical study, the authors determined that after the odor was gone after 2-5 days, Culture of swabs show a decrease or disappearance of anaerobic colonies. Adverse reactions of metronidazole did not occur, although this uncontrolled study reported the expected results (odor elimination).

Gethin et al. conducted an international descriptive cross-sectional on-line survey [24-28] to determine the current practice in the management of wound odor. A specific questionnaire in English, Spanish, Italian and German was emailed to wound care organizations worldwide, palliative and oncology nursing organizations. 1444 people from 36 countries responded. 46.7% of respondents encounter patients with MFW on a monthly basis around 811 patient. Topical Metronidazole gel was one of current practice in management of MFW odor that used by 56.9%, 87.9% of them reported this as being ‘somewhat effective’ or ‘very effective’. In this study large numbers who did respond from a range of health care settings support using of metronidazole gel for MFW odor management.

Another topical form of Metronidazole is tablets that might be crushed and mixed with sterile water to create either a 0.5% solution (5 mg/cc) or 1% solution. This is then used as a wound irrigate or a gauze is soaked in the solution and applied to the wounds. There is much anecdotal evidence to support this practice although little scientific evidence exists.

Lian et al. in a prospective randomized experimental study, comparing effectiveness of green tea versus topical Metronidazole powder in controlling malodor of MFW. 30 patients with malodorous MFW were randomized into either treatment green tea 15 patients or control group topical Metronidazole powder15 patients. All patients in both groups showed reduction in odor control by Day 7 without significant difference, this study give heath care provider alternative cost effective treatment for MFW. Metronidazole powder is used more often than metronidazole gel because it is very costly.

A systematic review of topical treatment to control MFWs odor done by Da Costa Santos et al. found that Metronidazole was cited in 10 studies The interventions ranged from the topical application of a gel or solution of Metronidazole in concentrations of 0.75%-0.8% to the treatment of the MFWs with crushed metronidazole tablets; on average, application took place once a day, and treatment lasted for 14 consecutive days. It found in this review that this treatment known in clinical practice to be effective for the control of MFW odor.

Conclusion

Topical metronidazole has spread use in clinical practice around the world; it is inexpensive, easy to use, and easily available. Despite the lack of clinical studies to support the use of topical metronidazole in treatment of malodor MFW. Perhaps the lack of data is due to the fact that many studies are conducted with terminal patients or that fungating wounds are relatively rare. Although this review did not find strong scientific evidence supporting the efficacy of topical metronidazole in control of malodor MFW through randomized clinical studies, this review provides the best available evidence to support the use of topical metronidazole in the treatment of patients with malodor MFWs. Health care provider can use topical metronidazole to manage malodor MFW, but additional researches in this area is still necessary.

Implications in Nursing Practice

This review paper will add basic knowledge regarding management of odor with Malignant Fungating Wound. Improve quality of life for cancer patient during illness trajectory, Improve social, psychological, and spiritual life for them. Help care provider to broaden knowledge about effectiveness of metronidazole. Help other researcher to study other clinical variable.

Declarations

Conflict of Interest

The Author(s) declare(s) that they have no conflicts of interest to disclose.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Authors’ Contributions

Rabia H, Fadi F. initiated and designed the review and formulated the first draft of the manuscript. Haneen T. critically reviewed the final manuscript.

References

  1. Probst S, Arber A, Faithfull S (2013) Malignant Fungating Wounds–The Meaning of living In an Unbounded Body. European Journal of Oncology Nursing 17: 38-45.‏
  2. Ferrell, Coylle, Paice, (2014). Oxford textbook of palliative Nursing, 4th Oxford University Press.
  3. Dowsett C (2002) Malignant fungating wounds: assessment and management. British Journal of Community Nursing 7: 394-400. [crossref]
  4. Ferrell B, Coyle N (2010) Oxford textbook of palliative Nursing, 3rd, Oxford University Press, New York.
  5. Naylor WA (2002) A guide to wound management in palliative care. International Journal of Palliative Nursing 11: 572-557. [crossref]
  6. Lo SF, Hu WY, Hayter M, Chang SC, Hsu MY, et al. (2008). Experiences of living with a malignant fungating wound: a qualitative study. Journal of Clinical Nursing 17: 2699-2708. [crossref]
  7. Graves ML, Sun V (2013) Providing Quality Wound Care at the End of Life. Journal of Hospice & Palliative Nursing 15: 66-74
  8. DaCSantos CM, De Mattos PCA, Nobre MRC (2010) A Systematic Review of Topical Treatments to Control the Odor of Malignant Fungating Wounds. Journal of Pain and Symptom Management 39: 1065-1076. [crossref]
  9. Clark, Jane (2002) Metronidazole gel in managing malodorous fungating Wound. British Journal of Nursing 11: 54-56.
  10. O’Brien C (2012) Malignant wounds Managing odour. Canadian Family Physician 58: 272-274.
  11. Lian S, XuY, Goh S, Aw F (2014) Comparing the Effectiveness of Green Tea verus topical Metronidazole Powder in Malodorous Control of Fungating Malignant wounds in a Controlled Randomized Study. Proceedings of Singapore Healthcare 23: 3-9.
  12. Bergstrom KJ (2011) Assessment and Management of Fungatin Wounds. Journal of Wound Ostomy & Continence Nursing 38: 31-37. [crossref]
  13. Grocott P, Gethin G, Probst S (2013) Malignant wound management in advanced illness: new insights. Current Opinion in Supportive and Palliative Care 7: 101-105. [crossref]
  14. Hampton S (2008) Malodorous fungating wounds: how dressings alleviate symptoms. British Journal of Community Nursing 13: sup. 31-38.
  15. Alexander S (2009) Malignant Fungating Wounds: Epidemiology, A etiology, Presentation and Assessment. Journal of Wound Care 18: 273-276.
  16. Gethin G (2010) Managing malodour in palliative care wounds in primary care. Nursing in General Practice.
  17. Alexander S (2009) Malignant fungating wounds: managing malodour and exudate. Journal of Wound Care 18: 374-382. [crossref]
  18. Lazelle-Ali C (2007) Psychological and Physical Care of Malodorous Fungating Wounds. British Journal of Nursing 16: 19-20.
  19. Draper C (2005) The management of malodour and exudate in fungating wounds. British Journal of Nursing 14: 4-12.
  20. Grocott P (1999) The management of fungating wounds. Journal of Wound Care 8: 232-234.
  21. Bower M, Stein R, Evans TRJ, Hedley A, Pert P, et al. (1992) A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. European Journal of Cancer 28: 888-8. [crossref]
  22. Finlay IG, Bowszyc J, Ramlau C, Gwiezdzinski Z (1996) The effect of topical 0.75% metronidazole gel on malodorous cutaneous ulcers. Journal of Pain and Symptom Management 11: 158-162. [crossref]
  23. Kuge S, Tokuda Y, Ohta M, Okumura A, Kubota M, et al. (1996). Use of metronidazole gel to control malodor in advanced and recurrent breast cancer. Japanese Journal of Clinical Oncology 26: 207-210. [crossref]
  24. Gethin G, Grocott P, Probst S, Clarke E (2014) Current practice in the management of wound odour: An international survey. International Journal of Nursing Studies 51: 865-874. [crossref]
  25. Adderley UJ, Holt IG (2014) Topical Agents and Dressings for Fungating Wounds. The Cochrane Library 2. [crossref]
  26. American Cancer Society (2009). Cancer Facts & Figures for Hispanics.
  27. Gibson S, Green J (2013) Review of Patients’ Experiences With Fungating Wounds and Associated Quality Of Life. Journal of Wound Care 22: 265-275. [crossref]
  28. Selby T (2009). Managing Exudate in Malignant Fungating Wounds and Solving Problems for Patients. Nursing Times 105: 14-7. [crossref]

Be True: A Theory on Bilateral Sway

DOI: 10.31038/PSYJ.2021352

Introduction

“The quest for truth is hard, but in some ways, it’s also easy” – Aristotle.

This theory attempts to identify and pinpoint exactly how and when many cancers, mental illnesses and other conditions may begin and unfold (tbd). Once understood, only then will we understand this information  is intended for the attention of those of us who care. Is this theory a novel way to consider and hence a probable, fact-based and pragmatic explanation about what some of us are searching for, in an attempt to resolve and gain a true understanding of many of those mental and physical health disorders and problems (which they are not; they are difficulties and challenges)?

By what process are each other’s personal ‘functional bilateral cohesive synthesis’ profiles determined? (The whole working quality of both sides. L/R) Does the outcome impact on and reflects in genetic regulation and functional mechanisms in each of our 11 body systems?

Effectively, would exploring the two fundamental questions suggested within this theory, further our understanding to help ‘balance the sway’ of what is arguably the largest unaddressed thorn in societies side today which, until purposefully investigated and hopefully appreciated, shall simply not go away?

This theory seeks to highlight a new alternative view on the possible origins of many individual neurological and physiological cases, and how they ‘become’ and develop. Then it queries: aren’t they natural? Is a chiral (conflict/accord) type effect involved? Are named labels misleadingly?

Realistically, could it be that bilateral sway associates with health & wellbeing on a comparably similar scale that e=mc2 associates with physics? Are there any limits or boundaries? (Self-esteem; Family; Education; Employment; Societal; Justice; Economy; Equality; Righteousness.)

Under what circumstances can this ‘balance of sway’ be considered to be ‘tipped’ (L or R) and could it be manipulated? What are the implications of Bilateral Sway? Please peruse, and critique where necessary, this theory & if you find it interesting, howsoever, share your views please.

Each on our own does not have the ability to work everything out, but we ALL may have something useful to say or indeed ASK! Initial feedback on this theory is indicative of ‘a unique perspective’/’very intriguing’/’needs to be investigated further’

N.B. There are 10 questions being asked above, all of which need answering!

To whomever it may concern (i.e. everyone), a ‘functional bilateral cohesive synthesis’ profile (the whole working quality of both sides) – which we each uniquely possess – may help to better explain, if understood, the multitude of disorders and dysfunctions, as well as talents and skills, being experienced today; whether neurological or phycological (particular emphasis being on many mental health conditions & diseases).*May help with: ‘Scientists have some idea, however……… haven’t worked out a cure yet’.

BUT HOW? Bilaterality is amongst the first, the most consistent and the most successful of all evolutionary trends that evolved around 575 million years ago.

Though bilateral, we are NOT mirror images of ourselves and the significance of this, however subtle, may be somewhat overlooked with respect to location & impact.

Starting from cell structure upwards, no two paired organs for example, within our bodies function/perform equally, resulting in a dominant/recessive partnership. Within our genetic makeup, the scale and scope of every possibility must truly be immense (‘Genetic sway’).

Examples worth noting are L/R hemispheres, eye dominance, nasal cycle and also handedness – some of the more obvious sensory functions. But what about all the other organs and functions within our body systems? And there are many, including the gonads!

Ideally, this ‘whole bilateral profile’ wants to be well balanced/homeostatic – no friction, no mutant behaviour. But as things are rarely just black and white, fluctuating shades of grey may appear throughout, indicating imbalances to varying degrees.

There is simply too much to get into & too many questions at this point, so please if I may, allow me to cut to and offer a concluding view for consideration in order to elicit some thoughts on this theory. (Maybe even some assistance/feedback if that is an option.)

Ultimately, and with respect to the five points above, many conditions arising – most notably in mental health – could be better appreciated & may actually be able to be pinpointed by enquiring and truly understanding the meaning behind the answers to two straight forward questions.

We each were created at the moment of conception from of a single sperm and a single egg. Sperm from the testes and an egg from the ovaries. This does not make sense: 1 sperm from both testes (L/R) and 1 egg from two oscillating ovaries (L/R). So how does that work then?

Understanding that paired organ partnerships can exhibit dominant or recessive traits (function) and hence could be considered bilaterally sensitive or influenced (performance), how does this manifest and what could the implications be?

Manifest

On a punnet square: L/L; L/R; R/L; R/R. (50:50 ratio)

i.e. 50 Bilateral; 50 Functional. Both are preferable, but only 1 possible. Ref: “Rule of thumb” experiment mentioned above.

Science generally implies that opposites are complimentary. Therefore L/R & R/L would appear compatible and want to function, though at the expense of Bilaterality. (50)

Conversely, Science also generally implies that likes are not complimentary. Therefore R/R & L/L would appear incompatible and not want to function, though reinforcing Bilaterality. (50)

Since no known mechanism for guiding contralateral/ipsilateral fertilisation exists, we most probably ‘could have been’ or ‘will be’ hoping and wishing for things to work out well, which is good, though being unaware of a notable, fluctuating 2:1 probability ratio attached. (Science, it seems, says nothing about this!) A very important point, nevertheless, is that all hopes and wishes invariably seem somehow honoured with a beautiful baby.

Implications

On a general empirical spectrum, and being conscious to avoid confusing the stereotypical ‘academic bank robber’ with the ‘school dropout surgeon’ 😉 – from a child that appears [naturally gifted/talented and may only struggle a little] to a child that appears to be [struggling somewhat, possibly, ‘for unexplained reasons’, yet tries hard] the possibilities seem endless, though currently stands at around 7.8 billion, or thereabouts, albeit the probabilities remain 2:1. These children become adult men and women & these adults can be seen everywhere from our churches, through to our jails and that’s neurological! For physiological viewing, you need to go from our churches, through to our hospitals & sadly sometimes back to the church.

SO!

The two questions, rhetorically speaking, essentially are:

1-Which paternal gonad (testi) produced the gamete (sperm) that helped create you? (L or R)

2-Which maternal gonad (ovary) produced the gamete (egg) that helped create you? (L or R)

Parental bilateral genetic profiles, were they to be known, would prove intriguing. Obviously, it is impossible to know what the answers to these questions are and has been throughout our ancestral history, though this doesn’t make it any less true or relevant when trying to understand the causes and reasons behind, and possibly an explanation for, both mental (neurological) and functional (physiological) conditions (good and not so good!).

Once created at conception, this unique bilateral genetic profile now begins to establish and then fulfil its role in ‘instructing’ how we individually will naturally function. The subsequent neurological, physiological, psychological, nutritional and environmental factors, which are all every bit as important, will start to play their respective roles in becoming decisive at ‘influencing’ how we each developmentally perform. We all carry two copies of each gene – alleles (outside of male sex chromosomes) – one from each parent. Very little, if anything, is known about differences, however subtle, within our DNA (genetic variation) from a bilateral sway perspective and its effects within out systems. This bilateral phenomenon influencing our DNA may be the main mechanism behind determining how genes are expressed along with chemical and molecular level factors. Varying abilities and/or disabilities, both neurological and physiological, could be the net result depending on how harmoniously balanced this new profile is. The potential contralateral/ipsilateral connectivity range encompassing both the dominant/recessive and L/R aspects (Functional & Bilateral) and resulting in 16 different possibilities is fundamental to understanding the concept of this theory. Half of these 16 variants could be what are responsible for causing many mutations! It may also explain why mutations (maybe excluding random) can be either beneficial or harmful (good & not so good!). Bilateral Sway may help to better explain Genetic Drift, which is described as a change in the gene pool that takes place strictly by change, resulting in genetic traits becoming lost or widespread in populations without respect to the survival or reproductive value of the alleles involved; also possibly resolving the “may or may not run in families” contradiction. This unquantifiable matrix of conditions, ranging from the admirable ones – such as prowess – through to others, considered less desirable – like disorders and dysfunctions – may in actual fact all is natural. They can only be the cumulative result of millions of years of continuous reproduction. A fluctuating 2:1 coefficient ratio at best, created generation within and after generation, establishing bespoke standards of a diverse global ‘bilateral’ gene pool through ever-changing combinations of diluting and/or strengthening chiral creation – ‘bilateral sway’. Though our TRUE bilateral profile is in essence largely invisible, it is no less real! Consider for example: Left or Right Handed? Left or Right eyed? Left or Right Eared? (For Information Purposes: there is also an automatic aspect at work and helping out elsewhere to varying degrees). Thinking in detail and in sequence or thinking creatively though appearing a little sporadic? Is there any evidence of cross or mixed dominance? These more neurological than physiological type questions may just be the easy ones as there could be many, many more, probably in increments of 23 or 46, depending on how it is viewed. (Rhetoric) Can you see a profile start to build? Can you see it in others? You see, it is invisible though it is there! But how balanced is it? True understanding & appreciation may be the only medicine capable of and required to conclusively address and resolve many cases. Appropriate prudence in deciding which route to take, either the “make better people” route or staying firmly and purposefully committed to the other “make people better” route could be instrumental and would prove beneficial. Pleading ignorance as a third option could well have its very own route, although should prove to be the one least travelled. To pause for now, I hope to have struck a chord of curiosity with someone, somewhere and that somehow, together, we can consider this theory (inclusive) further with a view to better understand it and if called for, a goal to resolving it. Please consider: Practice and passion are every bit a qualification as permits and permission! Should you wish to, please circulate this theory as you see fit.

Final Thought

If researching, check out: “What are the causes of……… (select any condition listed below). Explanations are offered for some and a few appear not even to be considered though many are preceded by comments such as: ‘the root causes are unknown’, ‘exactly what leads to ……… is not understood’, ‘the exact cause hasn’t been identified yet’ and so on. (This may take a moment or two or 25 years!)*It Doesn’t Sense Make, that whilst many causes remain unknown, to judge some conditions as disorders or dysfunctions (an illness) when in actual fact they may be natural, albeit undesirable. This approach, though well-intentioned, could be misguided and have negative effects for the psychological wellbeing of those considered as sufferers by contrasting them with those bilaterally swayed toward the assumed, understandably, more favourable direction within the spectrum (wellness). It also introduces STIGMA, a quality that resides further on up that third route. Addictive behaviour/Anxiety disorders/Asthma/Autism/Autoimmune disorders/ADHD/Bipolar disorder/Natural Athleticism function*/certain cancers/Depression/Diabetes/DYSLEXIA (including other co-morbid ‘Dys-‘ family members)/Eating disorders/Reliable Professional order*/Gender dysphoria (inclusive)/Migraines/Motor neurone disease/Multiple sclerosis/Tinnitus/Tourettes/Obesity/Ordinary Fun People Syndrome*/OCD/Paedophilia/Primitive reflexes (appreciation of these reflexes is of utmost importance)/PTSD/Schizophrenia/Sensory processing disorders/… This list in not exhaustive!(*What about: NAf, RPo, OFPS? Do these not count, or are they simply ignored? They ARE “disorders”/“dysfunctions”!)Lastly and sadly (though the author ‘wants’ to be incorrect, but understands he may not be), ‘Suicide behaviour disorder’. Proactively, purposefully and consciously swaying toward a ‘solution’, and quoting Socrates “the unconsidered life is not worth living”, best way we start considering ‘soonest!”).

BILATERAL SWAY – MANY MENTAL AND FUNCTIONAL CONDITIONS, GOOD AND NOT SO GOOD, COULD BE A DIRECT REFLECTION OF OUR TRUE FUNCTIONAL BILATERAL COHESIVE SYNTHESIS PROFILE.

Our whole working quality of both sides.

Thanks ‘very much’ for your time/consideration & hope to hear your thoughts.

Best  Regards

EMMET McMANUS

“For too long we have been battling this battle that won’t be won,until there is an understanding; then it will be for everyone”.

A personal message to ‘my guys’. Despite many years hiding beneath the covers and studying my pain, nobody hides pain better than a person who is trying to remain sincere, for the ones that they love unconditionally. Sometimes the sincerest people are the ones who love beyond many challenges, Cry behind closed doors and fight battles that nobody knows about.

BE TRUE: Be consistent with fact and reality.

Spatial and Temporal Variations in Physico-Chemical Parameters and Abundance of Mollusc Species in Shiroro Lake, Minna, Niger State

DOI: 10.31038/AFS.2021353

Abstract

Physico-chemical parameters, mollusc distribution and diversity in Shiroro Lake, Minna, Niger State was investigated between the months of March and August, 2017 spanning through the wet and dry seasons. Water samples for physico-chemical parameters and snails samples were collected and identified on monthly basis following standard methods. From the results; the temperature ranged from 26.5-32°C. The pH was all basic throughout the period of the study which ranged from 8.5-9.2 across all the stations. Dissolved Oxygen concentration ranged from 2.6-5.2 mg/L, while the BOD ranged from 2.2-4.9 mg/L. Nitrate level (0.43-0.83 mg/L) was high, while phosphate concentration (0.24-0.42 mg/L) was relatively low in all the sampling stations. A total number of 7 snail species were encountered. Station 3 had the highest number (403), station 2 with 363 species and station 1 had the lowest with 345 species. The family Viviparidae and Bithyniidae has 2 species each. The Bellamya phthinotropis has the highest number of species followed by Bellamya capillata; and the lowest was recorded among the species of Gebtella barthi. In general, the abundance of snails was higher during the rainy season than during the dry season. Taxa richness determined as Margalef index showed significant difference among the sampling stations. Similarly, diversity indices (Shannon Wiener, Simpson, dominance) also showed significant difference among the sampling stations. Lower values of diversity and Eveness indices were recorded at station 1. Station 2 had the highest record of diversity and eveness indices. Shiroro Lake is moderately organically polluted and adequate measures should be taken to check-mate this.

Keywords

Shiroro Lake, Physico-chemical parameters, Molluscs, Pollution and water quality

Introduction

Seasonal variations, pollution and its effects have over the years influenced the chemical contents of water and the survival of biotas in the aquatic environment. This is why it is difficult to understand the biological phenomenon fully because the chemistry of water levels tells much about the metabolism of the ecosystem and explains the general hydro-biological relationship (Basavaraja et al., 2011). Due to the pressures of increasing population and developing economy all over the world, the present situation of water quality management is far from satisfactory (Sawaya et al., 2003). Organic pollution is rampant in municipal water bodies posing health hazards to the neighbouring communities. Also, faecal pollution of drinking water causes water borne disease which has led to the death of millions of people [1]. The quality of drinking water is a complex issue and vital elements of public health. Poor water quality is responsible for the death of an estimated few million children annually (Holgate, 2000). The interaction of physical and chemical properties of water have a significant role in the composition, distribution and abundance of aquatic organisms which are therefore, used to determine the water quality and structural composition of aquatic community (Youne et al., 2003). Some of the major physico-chemical parameters that indicate water quality are the dissolved oxygen (DO) and biological oxygen demand (BOD). The dissolved oxygen is important in the natural self-purification capacity of the river; and the BOD is often used as a measurement of pollutants in natural and waste waters and to assess the strength of waste, such as sewage and industrial effluent waters [2]. BOD is an important parameter of water indicating the health scenario of freshwater bodies [3].

Gastropods are single-valve, soft-bodied class of animals in the phylum Mollusca. It is the largest, extremely diverse taxa that includes over 40,000 species of which 5,000 are fresh water snails found in wetlands like lakes, ponds and streams worldwide. Freshwater snails are an important food source for many fish, turtles, and other species of wildlife. As a result of their sensitivity to certain chemicals, many species are excellent water-quality indicators. Over the years, conservation and recovery efforts for freshwater snails include artificial culture or heliculture, water pollution control, and most importantly, habitat protection and restoration. Cleaning waterways not only improves the habitat for snails and other aquatic life, but it also improves the quality and supply of water for human consumption. Dam construction and other channel modifications, siltation, and industrial and agricultural pollution have all degraded the river habitats on which most species depend. As a result, the species richness and the abundance of freshwater snails have declined. Likewise, anthropogenic activities around the reservoir are on the increase, further compounding the problems and effects of pollution on the biota living within the aquatic habitat.

Shiroro Lake was constructed for domestic consumption within the Shiroro Local Government Area of Niger State and its environment. But there is little or no information about the snail’s distribution, diversity, and some selected physico-chemical parameters. This present research would serve as baseline information on the distribution, diversity of snails and changes in some physico-chemical parameters of the lake.

Materials and Methods

Description of the Study Area

Shiroro Lake was created with major objective of providing domestic water to Shiroro Local Government and its environment; however, fishing and irrigation have become other established uses of the reservoir. The area has a tropical climate with mean annual temperature, relative humidity and rainfall. The climate presents two distinct seasons: a rainy season and a dry season. The vegetation in the area is typically grass dominated savanna with scattered trees. The people are mostly engaged in agriculture, trading, artisanship and civil service for their living. Shiroro Lake was created in May, 1984 by damming the Kaduna River at Shiroro village, Niger State, Nigeria. Its coordinate is: Latitude 9.9724, Longitude 6.83532. The reservoir has an estimated surface area of 312 km2 and a mean depth of 22.4 meters and continues to grow. It is now the second largest man-made lake in Nigeria followed by Jebba. The Shiroro Lake, like most other large man-made lakes in Nigeria and throughout the tropics, was expected to provide favourable conditions for large scale fish production and fishery development in Nigeria.

Water Sampling

Monthly sampling of the three study stations were carried-out from March to August, 2017 during the period of wet and dry seasons. Water samples were collected using 1 L plastic container from three sampling sites and transported to the Laboratory of the Department of Water, Aquaculture and Fishery Technology (WAFT), Federal University of Technology, Minna. Parameters like temperature, total dissolved solid, dissolved oxygen, pH and electrical conductivity were measured immediately from the sampling sites (Figure 1).

fig 1

Figure 1: Map of the sampling stations of the Shiroro Lake, Niger State, Nigeria.

Snails Collection

Snails were collected from the study areas in the three sampling sites with the use of scoop net. Collected snails were transferred to a 1 L well labeled sample bottle with a cork and was preserved in 10% formalin. The samples were taken to the laboratory, viewed with the hand lens and subsequently identified using modified keys as described by [4] and pictorial diagrams.

Physico-chemical Parameters Analyses

Water Temperature

Water temperature at various sites were determined using mercury-in-glass thermometer which was immersed in water 6 cm below the water surface and left to stabilize for about two-five minutes before the readings were taken and recorded in °C.

DO, BOD, TDS, pH and EC Determination

Dissolved oxygen was determined with Hanna instrument (Hanna microprocessor pH /EC/TDS, P.R. (1970). This was done in duplicate for each site and each month of the sampling periods. The BOD was also determined using Hanna instrument after the samples had been incubated in the dark at laboratory temperature for five days. These were measured in mg/L. The Total Dissolved Solids (TDS in mg/L) and Electrical Conductivity (EC in µS/cm) were determined by the same instrument after rinsing in distilled water each time. The probe meter was standardized with buffer solutions of pH 4.0, 7.0, 9.0 before taking the reading for the pH in each station.

Sodium

Stock sodium was prepared by measuring 2.542 g of dried NaCl which was then diluted with a litre of distilled water. Intermediate sodium solution was prepared from stock solution by diluting 10 ml of stock solution with 100 ml distilled water. Standard sodium solution was then prepared from the intermediate sodium solution by diluting 10 ml of intermediate sodium solution with 100 ml distilled water. This was then used to prepare various concentrations in the range of 0.1 to 1.0 mg/L. The emission of these various concentrations was determined with a flame photometer at 589 nm. The Na content of the water sample was determined by measuring their emission with the flame photometer.

Potassium

Stock solution was prepared by dissolving 1.907 g of dried KCl crystal in distilled water which was then made up to 1 litre. Intermediate potassium solution was prepared by diluting 10 ml of stock potassium solution with 100 ml distilled water. Standard potassium solution was prepared by mixing 10 ml of intermediate potassium with 100 ml distilled water. Various concentrations in the range of 0.1 to 1.0 mg/L were prepared from the standard and were measured with flame photometer at 768 nm.

Nitrate

The nitrate concentration in the sampled water was determined using phenol disulphonic acid method. This method was carried out using spectrophotometer, laboratory glassware, hot water bath and reagents. Phenol disulphonic acid; 25 g of white phenol was dissolved in 150 ml (concentrated) and 85 ml of concentrated sulphuric acid was further added. The solution was heated until it dried out. 25 ml of water sample was placed in a porcelain basin and was evaporated to dryness on a hot water bath. 0.5 ml of phenol disulphonic acid (reagent 1) was then added to the residue and stirred with glass spatula. 5 ml of distilled water was added and 1.5 ml of potassium hydroxide solution (reagent 2) was also added. The mixture was thoroughly stirred by mixing. It turned yellow indicating the presence of Nitrate. The absorbance was read using spectrophotometer at 410 nm [5].

Phosphate

The concentration of phosphate in the water sample was determined by placing 25 ml of water sample in an Erlenmeyer flask and evaporated to dryness. The residue was cooled and dissolved in 1 ml of 70% perchloric acid (reagent 1). The flask was heated gently until the contents became colourless. It was cooled and 10 ml of distilled water was added together with 2 drops of Phenolphtalein indicator (reagent 2)_ this was prepared from 1.0 g of phenolphthalein dissolved in 100 ml of ethyl alcohol and 100 ml of distilled water. The above was titrated against sodium hydroxide solution (reagent 3) which was prepared by dissolving 4.0 g of the sodium hydroxide in 100 ml distilled water until there was an appearance of a slight pink colour. Volume was made up to 25 ml by adding distilled water; 1 ml of ammonium molybdate solution was added (reagent 4 made from 62 ml concentrated sulphuric acid and 80 ml distilled water and allowed to cool. 5 g of ammonium molybdate was then dissolved separately in 35 ml of distilled water and mixed with the sulphuric acid solution to 200 ml). 3 drops of stannous chloride solution (reagent 5_this was made from 0.5 g stannous chloride and dissolved in 2 ml hydrochloric acid and then, diluted to 20 ml with distilled water and used fresh). A blue colour indicates the presence of phosphate. The absorbance was recorded on spectrophotometer 690 nm after 10 minutes.

Data Analysis

One way Analysis of Variance (ANOVA) was used to determine the monthly variations in physico-chemical parameters using SPSS IBM (Version 20 for window) statistical package at P<0.05 level of significance. Taxa richness (Margalef and Menhnick indices), Diversity (Shannon and Simpson dominance indices), Eveness indices and Huctchenson T-test for inter-site comparison were determined using the computer basic programme SP DIVERS.

Results and Discussions

Monthly Variation in Physico-chemical Parameters of the Sampling Stations of Shiroro Lake, Minna Niger State

Water Temperature

The highest water temperature was recorded in station 1 with 30.5°C in the month of May and the lowest was recorded at station 1 in the month of August (Table 1).

DO. The highest dissolved oxygen was recorded in station 1 with 5.4 mg/L in the month of March and the lowest was recorded at station 2 in the month of August (Table 1).

BOD. The highest BOD was recorded at station 1 with 5.2 mg/L in the month of March and the lowest was recorded at station 2 in the month of August (Table 1).

TDS. The highest TDS was recorded in station 1 with 108 mg/L in the month of June and the lowest was recorded at stations 2 and 3 in the month of August (Table 1).

pH. The highest pH was recorded in station 1 with 10 in the month of March and the lowest was recorded at station 3 in the month of August (Table 1).

Electrical Conductivity. The Electrical conductivity for the three stations was the same through-out except for the Electrical conductivity of station 1 which increased slightly from 0.03 to 0.04 µS/cm in June (Table 1).

Sodium. The highest Sodium concentration was recorded in station 1 with 8.83 mg/L in the month of July and the lowest was also recorded at station 1 in the month of May (Table 1).

Potassium. The highest potassium concentration was recorded in station 3 with 4.11 mg/L in the month of March and the lowest was recorded at station 2 in the month of April (Table 1).

NO3. The highest Nitrate concentration was recorded in station 3 with 0.83 mg/L in the month of July and the lowest was recorded at station 2 in the month of March (Table 1).

PO4. The highest phosphate concentration was recorded in station 3 with 4.11 mg/L in the month of March and the lowest was recorded at station 2 in the month of April (Table 1).

Table 1: Summary of the physico- chemical parameters of the study stations in Shiroro Lake, Niger State from March to August, 2017. The highest and lowest values obtained during the sampling periods are indicated in parenthesis.

Parameter

Station 1  Station 2

Station 3

Temperature (0C)

28.1 ± 5.21(26.5-30.5)

27.9 ± 0.54 (26.7-29.4)

29.32 ± 0.95 (27-32)

pH

9.04  ± 0.04 (8.9-9.1)

8.8  ± 0.09 (8.6-9.0)

8.84  ± 0.11 (8.5-9.2)

Conductivity (µS/cm)

0.03  ± 0.02(0.03-0.04)

0.03  ± 0.00 (0.03-0.03)

0.03  ± 0.00 (0.03-0.03)

TDS (mg/L)

87.8 ± 5.21(79-108)

83.8 ± 3.10 (76-95)

83.4 ± 2.84 (76-91)

Dissolve Oxygen (mg/L)

3.95 ± 0.37 (3.0-5.2)

3.62 ± 0.37(2.6-4.8)

3.92 ± 0.36 (2.7-4.9)

Biological Oxygen Demand (mg/L)

3.26 ± 0.37(2.7-4.9)

3.00 ± 0.39 (2.2-4.5)

3.60 ± 0.34 (2.4-4.5)

Sodium (mg/L)

6.45 ± 0.85 (4.4-8.8)

6.85 ± 0.68 (4.5-6.6)

6.85 ± 0.49 (5.9-8.5)

Potassium (mg/L)

1.77 ± 0.15 (1.36-2.2)

1.72 ± 0.17 (1.26-2.16)

Phosphate (mg/L)

0.34  ± 0.03(0.26-0.42)

0.33  ± 0.02 (0.24-0.38)

0.31  ± 0.02 (0.27-0.36)

Nitrate (mg/L)

0.56  ± 0.06(0.43-0.73)

0.51  ± 0.05 (0.42-0.64)

0.58  ± 0.07 (0.45-0.83)

Abundance and diversity of snail species collected from Shiroro Lake. Total number of 7 species of snails was encountered during the study period. 2 species of Melanoides polymorpha were found in stations 2 and 3 but none in station 1. Ballamya phthinotropis was the major species with relative aboundance of 413 species (37%) followed by Ballamya capillata with 346 species (31%), Afrogyrus rodriguezensis with the total number of 178 species (16%) and Melanoides polymorpha with the lowest number of species (0.4%) (Table 2). Shannon index and Eveness index analyses showed that there were significant differences (P< 0.05) among the stations (Table 3).

Table 2: Spatial variations in snail species collected from Shiroro Lake, Niger State from March to August, 2017.

Species

Station 1 Station 2 Station 3 Species Total

%

Ballamya phthinotropis

154

108 151 413

37%

Ballamya capillata

106

128 112 346

31%

Lanitus intortus

43

33 63 139

12%

Afrogyrus rodriguezensis

42

83 53 178

16%

 Sierraia leonensis

2

3 2 7

0.6%

Gabtella barthi

8

6 20 34

3%

Melanoidees polymorpha

0

2 2 4

0.4%

Table 3: Taxa richness, Diversity, Eveness and Dominance Indices of Snail species collected from Shiroro Lake, Niger State from March to August, 2017.

Station 1 Station 2

Station 3

Taxa_S

17

23

19

Individuals

355

363

403

Dominance_ D

0.2352

0.1415

0.1156

Simpson_1-D

0.7648

0.8585

.8844

Shannon_H

1.918

2.377

2.45

Eveness_e^H/S

0.4003

0.4682

0.6101

Margalef

2.725

3.732

3.001

Taxa-S, Dominance_ D, Simpson_1-D, Shannon_H and Eveness_e^H/S stand for Taxa richness, Dominance Diversity, Simpson indices, Shannon indices and Eveness indices respectively.

Discussion

During the dry season the water temperature recorded was high in March, April, and May, 2017. This may be due to the increase in solar radiation (which is a usual phenomenon during dry season) during the period of the study. The mean water temperature obtained in this study was typical of tropical inland fresh water and river. This is in line with the findings of [6]. This is also in agreement with the studies of [7], [8] and [9] who also recorded high temperatures during the dry season. In addition, the relatively low temperature recorded in the months of June, July, August, 2017 may be due to the onset of the raining season and increasing water volume. This finding is also in agreement with the reports of [7] and [8].

The mean dissolved oxygen values obtained during the period of the study for the stations were low. The low level of DO probably indicated polluted nature of the water body. Similar low level of DO was reported in Dal Lake, Kashmir [10]. Monthly variations in DO for all the three stations were fluctuating. This fluctuation in the levels of DO could be as a result of differential influx of pollutants as run-offs from the neighbouring communities. It could also be due to rainfall regime pattern.

The BOD values indicate the extent of organic pollution in the aquatic system which affects the water quality [10]. Based on the BOD classification of [5], the mean BOD values in station 1 was high (2.7 mg/L), while stations 2 and 3 were low (2.4 mg/L) and (2.2 mg/L), respectively compared to that of station 1. The fluctuations in the BOD of each station and month probably indicate that the water in these stations was moderately polluted. This may be due to anthropogenic activities around the lake and the presence of the market at the lake side which may have led to organic pollution.

The monthly variations in Nitrate level were relatively high in all the sampling stations with the highest value of 0.83 mg/L in the month of July. Slightly higher range of values was reported in the studies of [12] in Bahir Dar Gulf of lake Tana, Ethiopia and [13] in a perturbed Tropical Stream in the Niger Delta, Nigeria; and [9] in River Galma, Zaria with 0.92-4.18 mg/L, 0.22-2.87 mg/L, 0.03 ± 0.0-1.11 ± 0.04 mg/L, respectively). Furthermore, the mean phosphate concentration ranged from 0.24-0.42 mg/L. This is higher than the mean values of 0.01 ± 0.01-0.20 ± 0.01 mg/L reported by [9]. Lower levels of phosphates, sulphates, nitrates indicate low level of organic pollution. The highest sodium content was recorded in July with 8.83 mg/L. This is probably because the most common source of elevated sodium levels in the lake water are: erosion of salt deposit and sodium bearing rock minerals, infiltration of surface water contaminated by road salt, irrigation and precipitation of leachate from landfill or industrial sites [14]. And during the rainy season there was influx of run-offs from the surrounding environment into the water body.

The EC in this research was very low (0.03 μs/cm) and would probably not pose any threat to the biota of the lake. The FEPA acceptable limit for conductivity in domestic water supply is 70 μs/cm [15]. Higher values were recorded from the same study site by [16]. This is also in contrast to the findings of [9] who reported a range mean value of 69.20 ± 3.12-157.80 ± 24.69 μS/cm in River Galma, Zaria. Likewise, the TDS are very low in comparison with previous studies. This may have arisen from improved maintenance of the lake.

The snail species in Shiroro Lake is highly diverse with Bellamya phthinotropis dominating the Shiroro Lake. The numerical density and species richness of snails were higher in the raining season than in the dry season. The snail species may have responded to changes in the water quality parameters as it was observed in changes in composition of species assemblage and abundance in the various sites. They may also have came out of their hiding places since there are now increased vegetation cover that could portend improved feeding and fertile ground for reproduction. Similar studies by [17] reported 29.06% relative abundance of mollusc in Obazuwa Lake, Benin city and attributed the abundance of the molluscs and oligochaetes in all the stations to the non-occurrence of habitat restriction in the study areas.

Conclusions and Recommendations

Anthropogenic activities and changes in season influenced the environmental conditions of the Shiroro Lake, thus affecting the snail species composition in each station. Overall results showed that changes in water quality of the Lake have significant effects on the structure, abundance and diversity of the snail species that were found. Station 3 had the highest number (403), station 2 with 363 species and station 3 had the lowest with 345 species. The family Viviparidae and Bithyniidae has 2 species each, the Bellamya phthinotropis has the highest number of individual species followed by Bellamya capillata and the lowest was recorded among the species of Gebtella barthi. In general the abundance of Snail was higher during the rainy season than during the dry season.

The highest DO was observed in the month of March with 5.4 mg/L, the highest Electrical conductivity was observed in the month of April with 0.4 (µS/cm), the highest TDS was observed in the month of April with 108 mg/L, the highest BOD was observed in the month of March with 5.2 mg/L. The variations in the phosphate, nitrates, sodium and potassium indicate that Shiroro Lake is organically polluted but do not pose any serious danger to the survival and adaptation of the biota.

More care should be taken to minimize the entry of pollutants into the water body so that the snails species and other biota of the Lake observed in this water body can be conserved.

References

  1. Adefemi SO, Awokunmi EE (2010) Determination of physico-chemical parameters and heavy metals in water samples from Itaogbolu area of Ondo-State, Nigeria. African Journal of Environmental Science and Technology 4: 145-148.
  2. Zeb BS, Malik AH, Waseem A, Mahmood Q (2011) Water quality assessment of Siran River, Pakistan. International Journal of Physical Sciences 6: 7789-7798.
  3. Bhatti MT, Latif M (2011) Assessment of water quality of a river using an indexing approach during the low-flow season. Irrigation Drainage 60: 103-114.
  4. Brown DS (2005) Freshwater snails of Africa and their medical importance. 3rd edn. London: Taylor and Francis e-Library 12-41.
  5. American Public Health Association (APHA) (2005) Standard Methods for the Examination of Water and Waste Waters. 20th edn. Washington DC 1134.
  6. Arimoro FO, Iwegbue CMA, Osiobe O (2008) Effects of industrial Waste Water on the physical and chemical characteristics of Warri River, a coastal water in the Niger Delta, Nigeria. Research Journal of Environmental Science 2: 209-220.
  7. Ezra AG (2000) Planktonic Algae in relation to the Physico chemical Properties of some Fresh Water Ponds in Bauchi, Nigeria. Nigeria Journal of Experimental and Applied Biology 1: 19-26.
  8. Ibrahim S (2009) A survey of zooplankton Diversity of Challawa River, Kano and Evaluation of some physic chemical condition. Bayero Journal of Applied Sciences 2: 19-2.
  9. Samuel PO, Adakole JA, Suleiman B (2015) Temporal and Spatial Physico-Chemical Parameters of River Galma, Zaria, Kaduna State, Nigeria. Resources and Environment 5: 110-123.
  10. Iqbal PJM, Pandit AK, Jaceel JA (2006) Impact of sewage waste from Human settlement om physic-chemical characteristics of Dal Lake, Kashmir. Journal of Research Development 6: 81-85.
  11. Jonnalagadda SB, Mhere G (2001) Water Quality of Odizi River in Eastern Highland of Zimbabwe. Water research 35: 2371-2376. [crossref]
  12. Imoobe TOT, Akoma AC (2008) Assessment of Zooplankton Communitiy Structure of the Bahir Dar gulf of Tana, Ethiopia. Journal of Environmental Studies and Management 1: 36-34.
  13. Arimoro FO, Oganah AO (2010) Zooplankton community response in a Perturbed Tropical Stream in the Niger Delta, Nigeria. The Open Environmental & Biological Monitoring Journal 3: 1-11.
  14. Butkus SN, Hermanson RE (2007) Washington State University Extension Sodium Content of your Drinking Water.
  15. DWAF (1996) South African Water Quality Guidelines. Domestic Uses. 2nd. Ed. Department of Water Affairs and Forestry, Pretoria 1.
  16. Kolo RJ, Oladimeji AA (2004) Water quality and some nutrient levels in Shiroro Lake Niger State. Nigeria. Journals of Aquatic Sciences 19: 99.
  17. Olomukoro JO, Oviojie EO (2015) Diversity and Distribution of Benthic Macroinvertebrate Fauna of Obazuwa Lake in Benin city, Nigeria. Journal of Biology, Agriculture and Health care 5: 94-100.

Mustard Surgery Three Months after a COVID-19 Infection: A Case Report

DOI: 10.31038/SRR.2021412

Abstract

Introduction: This past year, on a global scale, since 2019, public health warnings have gone off because of the recent epidemiological crisis set of the COVID-19 pandemic. This pandemic holds responsibility for millions of infections, manifesting broadly in its clinical presentation, which ranges from asymptomatic carriers to respiratory failure, myocardial pathology and death; increasing the rates of hospitalization. Pediatric patients are at high risk of contracting the disease including those with congenital cardiomyopathy that are in need of surgical intervention in order to survive.

Objective: Show that there exists an opportunity for elective surgical treatment and short term and medium term recovery in these patients in spite of respiratory and cardiovascular sequelae. Case presentation of an eleven-month infant diagnosed with Transposition of the Great Vessels, who after three months of idleness for having tested positive for COVID-19, received definitive surgical care for the initial diagnosis.

Results: The perioperative strategy was based in the probable sequelae due to the infection. There are not respiratory complications like consequence for the previous lung injury. The auriculoventricular dysfunctional immediate post-operative was related with the surgical technique.

Conclusion: A period no less than three months could be offer security for surgery using extracorporeal circulation in pediatric patients who suffered COVID-19. Patient with favorable post-op prognosis resulting from the work of a multi-disciplinary team that met all challenges of the complications inherent in the post-operative period following a complex cardiovascular surgery along with those of a potentially fatal virus.

Keywords

Congenital cardiomyopathy, Transposition of the great vessels, Mustard, COVID 19 disease, Surgery post COVID-19

Introduction

Since March 2019 and given the few studies published in this regard, it was believed that the coronavirus caused purely respiratory symptoms; However, as the number of patients with COVID-19 increased, it was observed that cardiovascular disease contributed to the worsening of the disease and darkened the prognosis of the infection. Patients with a history of cardiovascular disease make up the group with the highest risk of morbidity and mortality [1,2]. The data available to date indicate that COVID-19 can cause new cardiovascular complications or exacerbation of pre-existing cardiovascular diseases. It is estimated that myocardial injury can be found in between 7% and 17% of hospitalized patients, especially those admitted to the ICU. Patients with COVID-19 are at increased risk of acute myocardial infarction, myocarditis, heart failure, shock, arrhythmias, and sudden death in the acute phase of the disease. In COVID-19, ground glass opacities can be seen on chest radiographs, radiographic features similar to cardiogenic pulmonary edema [3-6].

In Chinese series, between 0.8 and 2% morbidity is reported in pediatric patients. In one of the largest reports published in China, of 731 pediatric cases with COVID 19, 90% were classified as asymptomatic (21%) , mild (58%) and moderate (19%) [7]. The clinical pictures are mild in most children, including infants, with short-term fever and catarrhal symptoms. However, even if they are mild cases, they can be an important source of transmission of the virus [8]. On July 5, 2021, in Cuba, children under 20 years old reached 630 and of them 562 in pediatric ages, accumulating a total of 29,583 to date [9].

Transposition of the great vessels (TGA) is a congenital heart disease in which the aorta arises from the right ventricle (RV) and the pulmonary artery from the left ventricle (LV); which produces a pathological relationship of the cardiac structures [10].

The prevalence of congenital cardiovascular malformations has not decreased; To this is added the serious epidemiological situation that not only our country is going through, but the world in general [11] Every year a limited group of patients with this heart disease is born, despite the vigilance and well-executed development of the Prenatal Diagnosis of Congenital Heart Disease program, together with this, family criteria to maintain the course of pregnancy and birth of the baby [12]. The correction of this cardiovascular malformation has several solutions depending on the characteristics of the associated anatomy and ventricular functions [13]. In this case, a physiological correction surgery was performed (Mustard Surgery), consisting of crossing the atrial circulation. In such a way that the desaturated blood from the vena cava goes to the left ventricle, the pulmonary artery and the lungs and the oxygenated blood from the pulmonary veins goes to the right ventricle, the aorta and the rest of the body. In the literature consulted, no reports of extracorporeal circulation surgery for congenital heart disease were found in children who suffered from COVID 19 disease, which motivates this presentation.

Presentation of the Case

Eleven-month-old male, white, with prenatal diagnosis by Transposition Echocardiography of the Great Arteries; in which anatomical correction surgery was contraindicated due to early detraining of the left ventricle, which was under outpatient follow-up to carry out the planned surgery (Surgery of Mustard), previous Rashkind and with previous medical treatment for his underlying heart disease with Furosemide (10 mg), aldactone (12 mg) and Digoxin (40 Mcg); At seven months of age, she began with an acute respiratory picture of light polypnea, nasal discharge with obstruction, intercostal drawing, and SO2 of 73%. Ag test and PCR were performed with positive results and his hospital admission was decided with a positive COVID-19 diagnosis. He was admitted to a Pediatric Intensive Care Unit since a history of congenital heart disease is a risk factor associated with severe clinical forms and complications [14].

The complementary examinations carried out reported:

Hemoglobin: 17 g/dl Hematocrit: 0.54 Leukocytes: 15 x 109/l Segmented: 14% Lymphocytes: 84% Platelet count: 302 x 109/l Creatinine: 67 mmol/l Glycemia: 7.3 mmol/l, D-dimer positive, with slight metabolic and lactic acidosis 5.1 mmol/l. Chest radiograph with evidence of bilateral inflammatory-lookinglesions (Figure 1).

fig 1

Figure 1: AP chest X-ray. Bilateral inflammatory lesions are seen.

Positive COVID

During admission, invasive mechanical ventilation was not necessary, he underwent symptomatic treatment [15] for fever with dipyrone, administration of fraxiheparin (0.3 vial/12 h) for 5 days and required antibiotic therapy with Ceftriazone for a period of 10 days at doses of 150 mg/kg/day, as well as dexamethazone. Under the criteria of clinical and radiological improvement, as well as the COVID-19 infection ruled out through a virological study, the patient was discharged after 20 days, with subsequent follow-up. He was evaluated during three months after discharge by Cardiology at the William Soler Cardiocenter, serial evaluation of EKG and chest X-ray. The chest X-ray showed microatelectasis lesions and slight pulmonary edema.

Echocardiogram

Transposition of the great vessels with closed ventricular septum, Boston type III, Aorta to the right and slightly anterior to the pulmonary. 15 mm balloon atrioseptostomy with left to right shunt. Moderate tricuspid regurgitation with TAPSE = 18 mm (Figure 2).

fig 2

Figure 2: Echocardiogram. Double barrel image.

After three months of convalescence and without evidence of sequelae from the viral infection, surgical intervention was decided. Mustard surgery was performed for definitive physiological correction, with extracorporeal circulation time of 113 minutes, aortic clamping time of 62 minutes at 23 degrees of temperature and modified hemofiltration once the extracorporeal circulation had concluded. Antimicrobial prophylaxis was used for 24 hours with Ceftriazone.

There were no complications during the surgical act and in the immediate postoperative period it evolved without major difficulties. Already in the PICU, he underwent treatment with captopril, aldactone and a diuretic pump. It was possible to separate from mechanical ventilation at 24 hours of It immediately evolved without major difficulties. Already in the PICU, he underwent treatment with captopril, aldactone and a diuretic pump. It was possible to separate from mechanical ventilation at 24 hours of operated with adequate tolerance and without risk of failure at weaning, with SO2>97%. On the third postoperative day, he presented a rhythm disorder (Figure 3) (bradycardia with complete atrioventricular block) that required placement of an external pacemaker, this complication is frequent in this type of surgery, secondary to atrial.

fig 3

Figure 3: EKG. Complete A-V lock.

After an 8-day stay in the PICU, he was transferred to the open ward where he was admitted under treatment and monitoring for another 15 days.

Hospital discharge at 23 days with treatment and monitoring by Cardiology and Cardiovascular Surgery, without complications or immediate sequelae.

Discussion

The current pandemic produced by COVID-19 also affects the Cuban population, until June 2021 more than one hundred and ninety thousand people have been infected, with more than a thousand deaths. Despite the fact that children were less affected at the beginning, the new strains have a higher incidence in children, with the development of severe forms that can trigger admissions to the PICU. Damage to the cardiovascular system is frequent, between. 8-20% [16]. The most reported cardiovascular manifestations are palpitations, orthostatic hypotension, hypertensive debut, myocarditis, pericarditis, rhythm disorders, and syncope.

The case study is an infant who suffered from the disease in the period when physiological correction surgery was planned for his underlying heart disease. Such surgery it requires adequate pulmonary functional capacity and pulmonary pressures within adequate parameters for tolerance [17]. The dysfunction can be asymptomatic, this justifies the need for close medical supervision. Stress tests in adults or adolescents may help prognosis, which is impossible in infants. When the dysfunction is advanced, the symptoms of heart failure appear, with respiratory distress, edema, fatigue, etc. n this phase the prognosis is at least reserved. It requires vigorous pharmacological treatment. This put the patient in a dangerous position and where studies and evaluation of respiratory function were required.

The patient in the current report was evaluated for three months after post-COVID discharge, with chest X-ray, EKG and echocardiogram awaiting possible sequelae reported in other patients. During this period, the patient remained with oxygen saturation according to the cyanosis caused by his heart disease, without worsening respiratory dynamics and stable hemodynamics. Once this time had elapsed, it was decided to carry out surgery. Physiological correction was carried out with satisfactory results. The patient did not develop sequelae that hindered the cardiovascular postoperative period or prolonged mechanical ventilation. It is likely that the preoperative strategy and the use of modified hemofiltration that improves the conditions of the cardiopulmonary block in the immediate postoperative period have contributed to the absence of sequelae and the promptness shown in the need for mechanical ventilation. Despite the absence of complications in this case, related to COVID-19 infection, working with the patient was a challenge; A multidisciplinary care team was in charge of the specialized care of this patient, anticipating in advance possible complications due to the unusual and novel association of the convalescent state of an infant due to COVID-19 and a complex cardiovascular surgery. No association studies have been published at the international level that favor a comparative point. Every day is a new challenge for health professionals and comprehensive medical care is sustained on the basis of experience. New research will open the horizons, making the treatments against this little-known disease more and more accurate. Strict compliance with prevention measures will help reduce the contagion of our pediatric patients and obtain a better evolution in those undergoing surgical treatment. The watchword is resilience, a commitment that each doctor has to grow in the face of adversity and create effective individualized strategies.

Conclusions

A period of no less than three months with monitoring of respiratory and cardiovascular sequelae could offer safety for congenital heart disease surgery with the use of extracorporeal circulation in infants who have suffered from COVID 19.

Conflict of Interests

The autors declare that does not exist an interest conflict.

Authors’ Contribution

Ilen Corrales Arredondo: she formulated the general objective of the article, looked for information and updated scientific evidence. Drafting of the document and its supervision.

Alfredo Mario Naranjo Ugalde: Led the planning of the report, as well as its mentoring and validation. Final revision of the manuscript.

Lais Angélica Ceruto Ortiz: She searched for updated scientific information and evidence. She performed the English translation and final revision of the manuscript. She narrowed the bibliographic references according to Vancouver standards. She performed the English translation and final revision of the manuscript. She narrowed the bibliographic references according to Vancouver standards. She wrote the document.

Yudith Escobar Bermúdez: she managed information data for the discussion of the case. She searched for up-to-date scientific evidence and information.

Pedro Rolando López Rodríguez: He searched for updated scientific information and evidence. Final revision of the manuscript.

References

  1. Xiong T, Redwood S, Chen M, Prendergast B, EurHeart J (2020) Coronavirus and the cardiovascular system: acute and long-term implications. 10:1-3 [crossref]
  2. Zheng YY, Ma YT, Zhang JY, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol [crossref]
  3. Driggin E, Madhavan MV, Parikh SA (2020) Cardiovascular Considerations for Patients, Health Care Workers, and HealthSystemsduringthe COVID-19 Pandem. Irving Medical Center, Columbia University, Journal of the American Collage of Cardiology, 75 : 2352-2371.
  4. Figueroa TJF, Salas MDA, Cabrera SJS, Alvarado  CCC, Buitrago SAF. COVID-19 y enfermedad cardiovascular. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular
  5. Kuba K, Imai Y, Rao S, Jiang C, Penninger JM (2006) Lessonsfrom SARS: Control of acute lung failure by the SARS receptor ACE J Mol Med , 84 :814-20. [crossref]
  6. Molina MM (2020) Secuelas y consecuencias de la COVID-19 13 : 71-77.
  7. Márquez AMP, Gutiérrez HA, Lizárraga LSL, Muñoz RCM, Ventura GST, etal. (2020) Espectro clínico de COVID-19, enfermedad en el paciente pediátrico. Acta Pediatr Méx, 41(Supl 1): S64-S71.
  8. Calvo C, Tagarro A, Otheo E, Cristina E (2020) Actualización de la situación epidemiológica de la infección por SARS-CoV-2 en España: Comentarios a las recomendaciones de manejo de la infección en pediatría. Cartas científicas, 92 :239-240.
  9. Sitio Web Oficial (2021) Ministerio de Salud Pública. Parte del cierre del día 5 de julio de.
  10. Cullum LM. Thesis MD (1967) The Natural History of Childrens with Transposition of the Great Vessels. Case Western Reserve University School of Medicine.
  11. Chih LC, Hernández DR, Jorge E (2020) Hospital Civil Fray Antonio Alcalde Cardiovascular and Metabolic Science. Cardiopatías congénitas , 31:Supp 4
  12. Armas PI (2019) Cuba con alta detección prenatal de Cardiopatías Congénitas.
  13. Albert HM (1955) Surgical correction of transposition of the great vessels. Surg Fórum, 5:74‐77. [crossref]
  14. Protocolo de Actuación Nacional para la covid-19. Cuba. (2021)
  15. DeCarvalho PCAP, Brunow-de CW, Johnston C, Souza RI, Figueredo DA(2020) COVID-19 Diagnostic and Management Protocol for Pediatric Patients. Clinics , 75: e1894. [crossref]
  16. Hu H, Ma F, Wei X, Fang Y (2020) Coronavirus fulminant miocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J, ehaa190. [crossref]
  17. Villagrá AS (2021) Transposición de grandes arterias operada con técnica de Mustard o Senning. Evolución a largo plazo. Unidad de Cardiopatías Congénitas (UCC)Clara del Rey 59, 1º E 28002 Madrid – España.

The Anthropocene and Its Relationship to Planetary Health

DOI: 10.31038/JPPR.2022511

 
 

In recent decades, man has become a geological force, competing with natural forces in the impact and modification of the Earth system. The term Anthropocene was proposed by scientists Paul Crutzen and Eugene F. Stoemer, in 2000, to describe this new time and emphasize the preponderant role of man in geology and ecology. There is no doubt that man has unequivocally and in some cases irreversibly changed the Planet, and that Holocene concepts can no longer be used to describe trends in chemical and biological variables and the future of the Earth system as a whole. Tomorrow depends, to a great extent, on actions to optimize the relationship between man and the environment. This, then, is the moment we find ourselves in today: the Epoch of Humans. The one in which Homo sapiens finds that civilization has become a force of planetary reach and of geological duration and scope. We are billions of people in the world and we continue to multiply.

From a biological point of view, it is a growth equivalent to that of a colony of bacteria: na extremely explosive pace, in a very short period of time. We have become planetary: today there is not a single region that is not directly or indirectly affected by the whole of human activity. By releasing smoke from automobiles, chimneys and fires, humanity changed the composition of carbon in the atmosphere, causing a temperature increase of 1°C, glaciers melting and sea level rise by, so far, 20 centimeters. Not to mention how humanity physically altered the planet, with concrete and steel. A clear example is the rivers: in the last decades, we have transformed the river courses of all the hydrographic basins of the world by building 40 thousand dams. If the reservoirs of all these dams were placed side by side, we would have a flooded area equivalent to the State of Bahia.

In na article published in the bulletin of the International Geosphere-Biosphere Program, Crutzen defended his thesis by saying that the rate of urbanization has increased tenfold in the last century and that, in a few generations, humanity will extinguish the fossil fuels generated over the last hundreds of millions of years. The text had na almost immediate repercussion among geologists. Scientist Andrew Gale of the University of Portsmouth, a member of the Geological Society of London, told The Times newspaper that he agrees with the argument of the chemist and his fellow geologists. According to him, human activities have become the main force behind the great changes in topography and climate. According to him, you cannot have 6.5 billion people living on a planet the size of ours and exploit every possible resource without causing gigantic changes in the physical, chemical and biological environments, which will be dramatically reflected in our geological record.